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Summary 
 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases involved in the 
regulation of diverse important cellular functions. The members of PI3K class I exhibit dual 
enzymatic specificity both as lipid kinases and protein serine kinases, and they are known to 
be indispensable for the development and proper functions of T lymphocytes. The 
involvement of PI3Ks in the activation of T cells is clearly demonstrated and so far mostly 
related to the PI3K class IA enzymes (a, b  and d isoforms), but it was found that PI3Kg, the 
single member of class IB PI3K, is also involved in the regulation of activation-induced 
proliferation and cytokine production of T cells. How PI3Kg participates in this mechanism is 
largely elusive. 
Earlier reports proved that PI3Kg KO mice have a reduced number and an impaired 
differentiation of thymocytes, as well as a reduced number of CD4 T cells in spleen. We 
confirmed this earlier findings regarding disrupted differentiation of PI3Kg-/- thymocytes, but 
in addition results presented here showed that this gene disruption had an even stronger 
impact on the mouse phenotype, significantly reducing the number of T cells in spleen and 
lymph nodes and effecting both major subpopulations of mature T cells (CD4 and CD8 cells). 
In published studies PI3Kg-/- T cells showed reduced proliferation upon T cell receptor 
(TCR) stimulation. Costimulation with specific anti-CD28 antibody or activation with 
Ionomycin and phorbol ester is able to rescue this proliferation, in contrast to subsequent 
interleukin-2 (IL-2) and interferon-g production. In our experiments IL-2 costimulation of 
TCR-activated PI3Kg-/- T cells was also sufficient to rescue this impaired proliferation, which 
clearly implicated that the lack of cytokines may be the major cause of their functional defect. 
 In order to elucidate how PI3Kg couples the activation of TCR and IL-2 production in 
Jurkat cells, we used the PI3Kg specific inhibitor AS041164. In our experimental settings 
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AS041164 did not exhibit any detectable cytotoxicity within the applied concentration range. 
Furthermore, this substance had no significant influence on overall PI3K activity in Jurkat 
cells proving its selectivity and specificity in our model.  
The results obtained by applying AS041164 on Jurkat cells implicated that PI3Kg may 
not be involved in the signalling events in the proximity of activated TCR, and that PI3Kg is 
dispensable for certain aspects of T cell activation, such as CD69 expression. Nevertheless, 
treatment with AS041164 clearly and reproducibly reduced IL-2 production of activated 
Jurkat cells in dose-dependent manner. Jurkat cells have constant high level of PIP3, the 
major product of PI3K lipid-kinase activity; therefore it is most likely that this effect was 
caused by a lack of PI3Kg protein kinase-activity.  
PI3Kg specifically interactions with several isoforms of protein kinase C (PKC) in 
Jurkat cells were also proved in this thesis. These interactions seem to be important for the 
proper function of interacting PKC isoforms upon T cell activation and for the subsequent IL-
2  production. Finally, our results showed that PI3Kg may be involved in the control of IL-2 
production on several levels from transcription to secretion, and one of these levels is 
apparently PKC-related. 
In conclusion, results from this thesis clearly demonstrate that PI3Kg is an important 
modulator of thymocyte proliferation and differentiation. Moreover, PI3Kg is necessary for 
the TCR-induced IL-2 production, a process known to be crucial for the normal proliferation 
of T cells after antigen receptor activation. PI3Kg  interacts with several PKC isoforms and 
modulate their activity upon TCR engagement, which is necessary for the IL-2 production. 
Described interactions depend on overall PI3K lipid-kinase activity as well as PI3Kg protein-
kinase activity. This various modes of protein-protein interactions and kinase activity clearly 
show the PI3Kg is a multifunctional enzyme important for proper development and function 
of lymphocytes. 
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Zusammenfassung 
 
Phosphorinositol-3- Kinasen (PI3Ks) gehören zu einer Lipidkinasenfamilie, die an der 
Regulation verschiedener zellulärer Funktionen beteiligt ist. Die Enzyme der PI3Ks Klasse I 
besitzen eine doppelte Spezifität, sowohl als Lipidkinasen, als auch als Proteinserinkinasen. 
Sie sind dafür bekannt bei der Entwicklung und Funktion von T- Lymphozyten unverzichtbar 
zu sein. Die Beteiligung der PI3Ks an der Aktivierung von T-Zellen wurde hauptsächlich den 
PI3K IA Klasseenzymen (a, ß, d  Isoformen) zugeordnet. Man entdeckte jedoch, dass PI3K?, 
ein einzelnes Mitglied der PI3K IB Klasse, auch bei der Regulation der durch Aktivierung 
induzierten Proliferation und Zytokinproduktion der T- Zellen eine Rolle spielt. In welcher 
Weise PI3K? an diesem Mechanismus beteiligt ist, ist in großen Teilen noch nicht  bekannt. 
Aus früheren Experimenten mit PI3K? Knockout Mäuse ist bekannt, dass diese 
sowohl eine geringere Anzahl und eine eingeschränkte Differenzierung der Thymozyten, als 
auch eine verringerte Zahl CD4+ T-Zellen in der Milz aufweisen. Wir konnten diese frühere 
Endeckungen, die die gestörte Differenzierung in PI3K?-/- Thymozyten betreffen, bestätigen, 
jedoch belegen unsere hier dargestellten Ergebnisse auch, dass diese Gendisruption sogar 
einen stärkeren Einfluss auf den Mausphänotyp hat. So kommt es zu einer signifikanten 
Verringerung der T- Zellen in der Milz und den Lymphknoten und zu einer Beeinflussung 
beider Hauptpopulationen reifer T- Zellen (CD4+ und CD8+ Zellen). 
In publizierten Studien zeigten PI3K?-/- T- Zellen eine reduzierte Proliferation 
bezüglich der T-Zellrezeptor  (TCR) Stimulation. Eine CD28 Kostimulation oder eine 
Aktivierung mit Ionomycin und Phorbolester  ist in der Lage diese gestörte Proliferation, im 
Gegensatz zu anschließenden Interleukin-2 (IL-2) und Interferon-? Produktion, aufheben. In 
unseren  Experimenten war auch eine IL-2 Kostimulation der TCR- aktivierten PI3K?-/- T- 
Zellen fähig, die gestörte Proliferation wiederherzustellen, was deutlich zeigt, dass ein Fehlen 
der Zytokine die Hauptursache ihres funktionellen Defektes sein könnte. 
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 Um aufzuklären, auf welche Weise PI3K? die Aktivierung des T- Zellrezeptors mit 
der IL-2 Produktion in Jurkat Zellen verbindet, wurde der spezifische PI3K? Inhibitor 
AS041164 verwendet. In unserem experimentellen Rahmen wies AS041164 in der 
applizierten Konzentrationsbreite keine detektierbare Zytotoxizität auf. Die Substanz hat 
keinen signifikanten Einfluss auf die PI3K Gesamtaktivität in Jurkatzellen, was ihre 
Selektivität in unserem Modell beweist. 
Die mit dem spezifischen Inhibitor AS041164 erzielten Ergebnisse implizieren, dass 
PI3K? nicht in Signalwege in der Nähe des aktivierten TCRs verwickelt ist, und dass das 
Enzym für bestimmte Aspekte der T-Zellaktivierung, wie die CD69 Expression, verzichtbar 
ist. Dennoch verringerte die Behandlung mit AS041164 deutlich und reproduzierbar die IL-2 
Produktion in aktivierten Jurkat Zellen in einer dosisabhängigen Weise. Jurkat Zellen besitzen  
einen konstant hohen Spiegel an PIP3, dem Hauptprodukt der PI3K Lipidkinase Aktivität, 
daher ist es am wahrscheinlichsten, dass dieser Effekt durch ein Fehlen der Proteinkinase 
Aktivität der PI3K? verursacht wird. 
Im Rahmen der Arbeit wurde klar gezeigt, dass PI3K? spezifisch mit verschiedenen 
Isoformen der Proteinkinase C  (PKC) in Jurkatzellen interagiert. Es hat den Anschein als 
seien diese Interaktionen für die richtige Funktion der interagierenden PKC Isoformen bei der 
T- Zellaktivierung und für die IL-2 Produktion wichtig. Abschließend zeigen unsere 
Ergebnisse, dass PI3K? in die Kontrolle der IL-2 Produktion auf verschiedenen Ebenen von 
der Transkription bis zur Sekretion verwickelt ist und dass eine dieser Ebenen anscheinend 
mit der PKC zusammenhängt.  
Zusammengefasst zeigt diese Studie klar, dass PI3K? ein  wichtiger Modulator der 
Thymozytenproliferation und- differenzierung ist. Darüber hinaus ist PI3K? für die TCR- 
induzierte IL-2 Produktion wichtig, einem Prozess, der entscheidend für die normale T- 
Zellproliferation nach der Antigen- Rezeptor Aktivierung ist. PI3K? interagiert mit 
verschiedenen PKC Isoformen und moduliert ihre Aktivität bezüglich der TCR Bindung, was 
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für die IL-2 Produktion nötig ist. Die beschriebenen Interaktionen hängen sowohl von der 
gesamten PI3K Lipidkinase Aktivität, als auch von der PI3K? Proteinkinase Aktivität ab. 
Diese verschiedenen Arten von Protein- Protein Interaktion und Kinase Aktivität zeigen klar, 
dass PI3K? ein multifunktionales Enzym ist, das für eine ordnungsgemäße Entwicklung und 
Funktion von Lymphozyten wichtig ist. 
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1. Introduction 
 
1.1. Cell signalling 
All eukaryotic cells have elaborate system of proteins that are capable to convert an 
extracellular signal into an intracellular biochemical event or process, and this signal 
transformation is commonly known as signal transduction. These refined signalling 
mechanisms enable intercellular communication and coordination of many physiological 
processes. Cellular signalling systems include different kinds of proteins: cell-surface and 
intracellular receptor proteins, protein kinases, protein phosphatases, adaptor proteins, GTP-
binding proteins and many other which interact with above mentioned signal transducers. All 
the proteins involved in signal transduction, regardless whether they catalyse particular 
biochemical reactions or facilitate interactions of other proteins, exhibit high selectivity for 
their targets (Alberts et al, 1994).  
Numerous types of cell receptors can recognise a huge variety of specific external 
stimuli, activate appropriate intracellular signalling pathways and transmit a signal to different 
sites within the cell. The results of the signalling processes are manifolds, including changes 
in cell metabolism, changes of the cytoskeleton and of cell motility or, as drastic as cellular 
suicide (programmed cell death). Many signalling pathways transmit their signals to the 
nucleus where trough activation or inhibition of different transcription factors fundamental 
changes in gene expression can occur. 
 
1.2. T cells, lymphocytes and other cells of immune system 
During evolution all higher organisms developed a complex system for the protection 
of their organism from foreign pathogens. This system, known as immune system, is entirely 
based on the function of highly specialised cells called leukocytes, commonly known as white 
blood cells. The first line of an organism’s defence is innate immunity, a part of the immune 
system that provides an immediate response to a wide range of pathogens. The innate 
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immunity mostly involves macrophages and all granulocytes (neutrophils, eosinophils and 
basophils). T and B lymphocytes are cellular components of adaptive immunity, a system that 
provides a highly specific immune response enabled by the presence of specific antigen 
receptors on the cell surface of lymphocytes. The adaptive immune response, unlike the 
innate immune response, requires prior exposure to pathogens and, in many cases, provides 
lifelong resistance to the same pathogen.   
Leukocytes originate in the bone marrow along with other blood cells, and they all 
derive from the same progenitors – pluripotent haematopoietic stem cells. These pluripotent 
cells produce two more specialised types of stem cells: a common lymphoid progenitor that 
gives rise to T and B lymphocytes, and a common myeloid progenitor that gives rise to 
erythrocytes, megakaryocytes and different other types of leukocytes. A brief overview of the 
blood cell differentiation is given in Figure 1.1. B cells mature in the bone marrow, while T 
cells complete their differentiation in the thymus. Immature T cells in the thymus or 
thymocytes undergo a complex process of differentiation, and distinct phases of this process 
are marked with changes in their cell surface molecules. Components of the T cell receptor 
(TCR) along with CD4 and CD8 co-receptor proteins are most important for distinguishing 
different stages of thymocyte differentiation. The cells in the first stage of development are 
called ‘double-negative’, because they do not express CD4 and CD8. The majority of 
thymocytes from this phase proceeds into the next step by becoming ‘double positive’ cells 
which express both CD4 and CD8. At this stage thymocytes start to express pre-T-cell 
receptor and they enlarge and divide. Later they become small, resting double-positive cells 
expressing low levels of TCR. Most of them fail positive selection and undergo apoptosis. 
Those who survive lose expression of either CD4 or CD8, become ‘single-positive’ 
thymocytes, and, after maturation, exported from the thymus.  
  1. Introduction 
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Figure 1.1. Differentiation of blood cells. All blood cells, including lymphocytes, 
arise from haematopoietic stem cells in the bone marrow. The first step in the differentiation 
of these pluripotent cells are two more specialised types of the stem cell, the common 
lymphoid progenitor that gives rise to the B cells, T cells and natural killer cells, and the 
common myeloid progenitor that gives rise to different types of other leukocytes, erythrocytes 
and megakaryocytes. Natural killer cells, unlike other lymphocytes, lack the antigen-
specificity and they are a part of the innate immune system. Other leukocytes that belong to 
the myeloid linage are monocytes which give rise to mast cells and macrophages, dendritic 
cells and three types of granulocytes: neutrophils, basophils and eosinophils. Macrophages 
and dendritic cells are known as professional antigen presenting cells. They engulf pathogens 
and antigens, expose them on the cell surface and by contact activate antigen specific T cells 
(modified after Janeway et al., Immunobiology, 5th ed., 2001). 
 
There are three major subsets of mature T lymphocytes: CD8 T cells or cytotoxic T 
cells, and two types of CD4 T cells or helper T cells – TH1 cells activate macrophages (and B 
cells) while TH2 cells stimulate B cells to differentiate. Mature T and B lymphocytes circulate 
between the blood and the lymphatic system and guard peripheral tissues. After encounter 
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with an antigen, lymphocytes become activated, start to proliferate (a process known as clonal 
expansion), and finally differentiate into effector cells capable to fight with the infection. B 
cells become antibody-secreting plasma cells, whereas T cells differentiate into effector T 
cells whose function depends on the sub-type of each activated T cell. 
 
1.3. Activation of T cells 
 
The T cell receptor (TCR) is a rare example of a receptor complex which determines 
many aspects of the cell function during the whole life span of a single T lymphocyte. From 
development and differentiation of a T cell to its activation, clonal expansion, effector 
function and apoptosis or survival, TCR is capable to deliver various signals that can result in 
completely different cell fate decisions (Werlen et al., 2003). This capability is enabled by the 
huge complexity of the TCR signalling process that involves numerous signalling proteins.  
T cell activation by contact with an antigen induces antigen specific T cell clonal 
expansion and differentiation. This response is regulated by signal transduction pathways 
initiated by the antigen receptor (TCR) and costimulatory molecules. An antigen is by default 
a foreign peptide bound to major histocompatibility complex (MHC) molecules presented on 
the surface of professional antigen presenting cells, such as dendritic cells. TCR is comprised 
of an a/b  subunit that recognises the antigen-MHC complex and signal transduction subunits 
g, d, e (CD3 complex) and z chains. 
Binding of antigen-MHC to TCR initiates signalling processes by recruiting and 
activating protein tyrosine kinases (PTK) of Src, Syk and Tec families (Lin & Weiss, 2001; 
Cantrell, 2002). TCR does not have any intrinsic kinase activity, but conformational changes 
induced by the activation of TCR expose immunoreceptor tyrosine-based activation motifs 
(ITAM) of the signal transducing subunit (CD3 and z chain) allowing their phosphorylation 
by Lck, a member of Src kinase family. The z-chain associated protein kinase of 70 kDa 
(ZAP-70), a member of the Syk family, binds to phosphorylated ITAMs via its tandem Src-
homology 2 (SH2) domains. This sets off phosphorylation and activation of ZAP-70, which 
  1. Introduction 
 5
leads to the subsequent phosphorylation of its substrates, such as linker of activated T cells 
(LAT) and Src homology 2-domain-containing leukocyte protein of 76 kDa (SLP-76). A 
major negative regulator of these initial TCR activation steps is the transmembrane tyrosine 
phosphatase CD45 that is also responsible for maintaining the basal level of Lck activation 
(Cantrell, 2002). 
LAT and SLP-76 are just two among a growing number of adapter proteins involved 
in TCR signal transduction. Their major role is to couple tyrosine kinases to the downstream 
effectors by forming scaffolds to assemble signalling protein complexes in the correct 
intracellular location (Simeoni et al., 2005a). At this point signals emerging from the 
triggered TCR disseminate from the inner side of the plasma membrane to different signalling 
pathways that end in the nucleus. This links TCR to the signalling pathways indispensable for 
T cell activation. One of such pathways is the activation of Ras- and Rho-family guanine 
nucleotide binding proteins (GTPases). These GTPases are essential during T cell 
development, while in mature T cells they appear to be essential for the activation of the 
mitogen activated protein kinase (MAPK) pathway, which is necessary for the induction of 
proliferation, actin skeleton rearrangement and cytokine production upon activation.  
Early events in TCR signalling include activation of enzymes which are involved in 
metabolism of inositol phospholipids. Phospholipase C gamma 1 (PLCg1) is recruited to the 
plasmamembrane and activated by tyrosine kinases (Lck, ZAP70, Itk and Rlk). Activated 
PLCg1 hydrolyses phosphatidilinositol(4,5)biphosphate (PtdIns(4,5)P2) and produces 
diacylglycerol (DAG) and inositol(1,4,5)triphosphate (Ins(1,4,5)P3). DAG binds to the 
specific domains in a number of signalling proteins, while Ins(1,4,5)P3 initiates an increase in 
intracellular calcium. These two events set off the activation of protein kinase C (PKC) and 
protein kinase D (PKD) isoforms among other enzymes, and they seem to be the key steps of 
TCR receptor triggering. The increased intracellular Ca2+ also activates calcium-calmodulin-
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dependent phosphatase calcineurin, resulting in nuclear translocation of the transcription 
factor known as nuclear factor of activated T cells (NFAT).  
TCR activation also stimulates the activity of phosphatidilinositide 3-kinases (PI3Ks). 
The product of their kinase activity is phosphatydilinosytol(3,4,5)triphosphate 
(PtdIns(3,4,5)P3), an important second messenger. It is known that PI3K activation occurs 
within seconds of TCR activation, and PI3Ks remain active for nine hours or more (Costello 
et al., 2002). The molecular mechanism by which TCR is coupled to the PI3Ks remains 
unclear, but it is known that these enzymes are essential for T cell activation and proliferation 
(Okkenhaug & Vanhaesebroeck, 2003b).  
The above described main signalling pathways emerging from activated TCR, along 
with other signalling events, culminate in the activation of transcription factors in the nucleus, 
including nuclear factor kappa B (NFkB), nuclear factor of activated T cells (NFAT) and 
activating protein-1 (AP-1). These factors initiate transcription of genes required for 
differentiation, proliferation as well as effector actions of activated T cells. 
Proliferation and differentiation of activated T cells are driven by the cytokine 
interleukin 2 (IL-2), which is produced by the activated T cells itselves. In addition, IL-2 is 
known to stimulate B cells, natural-killer (NK) cells, monocytes, macrophages and 
oligodendrocytes. Human IL-2 is a protein with globular structure consisting of 133 amino 
acid residues and predicted molecular mass of 15.4 KDa. Its synthesis is one of the earliest 
effects of T cell activation and it coincides with the synthesis of the a chain of IL-2 receptor 
(also known as CD25). The expression of this receptor chain on the cell surface is considered 
as an early marker of the activation. The IL-2 receptor (IL2R) has three chains: a, b  and g. 
Resting T cells express the bg heterodimer which has moderate affinity for IL-2, while the 
abg heterotrimer of activated cells has a high affinity, allowing the cells to respond to very 
low doses of IL-2. In primary cells costimulatory signals (like CD28 co-receptor activation) 
are necessary for the production of IL-2: it requires the coordinated action of several 
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signalling pathways that integrate on the level of multiple transcription factors, including 
aforementioned NFAT, AP-1, NK-kB and Oct-1 (Jain, et al., 1995; Eder et al., 1998).  
 
 1.4. Phosphoinositide 3-kinases 
Phosphoinositide 3-kinases (PI3Ks) are a family of evolutionarily conserved lipid 
kinases involved in regulation of diverse biological functions, including cell growth, 
differentiation, survival, proliferation, migration and metabolism. All enzyme members of this 
family phosphorylate the 3-position of the inositol ring of their substrates (Figure 1.2). These 
enzymes, isolated from a wide range of species, share a high sequence homology within their 
kinase domain. Based on their substrate, specificity and utilisation, their structure and 
regulatory mechanisms, PI3Ks are divided into four distinct classes, referred to IA,  IB, II and 
III (Domin&Waterfield, 1997).  
 
Figure 1.2. Phosphatidylinositol (PtdIns). Inositol-containing lipids are a class of 
phospholipids consisting of phosphatidic acid to which an inositol ring is attached via its 1’    
-OH group. In the scheme phosphatidylinositol is presented without any phosphate group on 
the inositol ring. In living cells all free -OH groups except for the 2’ and 6’ groups can be 
phosphorylated in different combinations. These phosphorylated forms of 
phosphatidylinositol are cold phosphoinositides (PIs) and each of them has a specific function 
inside the cell. Enzymes members of the PI3K family phosphorylate position 3’ of the inositol 
ring.  
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The class II PI3K family consists of three members: PI3K-C2a and PI3K-C2b  are 
expressed ubiquitously, whereas PI3K-C2g is expressed primarily in hepatocytes. Their size is 
approximately 170 KDa. All enzymes of this class phosphorylate PtdIns and PtdIns(4)P and 
PtdIns(4,5)P in vitro to generate PtdIns(3), PtdIns(3,4)P2 and PtdIns(3,4,5)P3, respectively, 
with a strong preference for PtdIns over PtdIns(4)P or PtdIns(4,5)P2. Nevertheless, their 
activity and their function in vivo are poorly described. It is known that epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), insulin, integrin ligation, and the 
chemokine known as monocyte chemoattractant protein (MCP-1) can induce increased lipid 
kinase activity in class II PI3K. Class II PI3Ks have two distinct domains at their C termini. 
The first, pox homology (PX) domain can bind PtdIns(3)P and PtdIns(3,4)P2 and in this way 
recruits class II PI3Ks to the plasmamembrane. The function of their second domain, a C2 
domain, is not clear, but it is confirmed that it can bind to phospholipids in a Ca2+-
independent manner in vitro. Unlike the members of class I PI3Ks, adaptor molecules for 
class II enzymes are not described so far. The cellular localisation of class II PI3K is also not 
clearly defined – conflicting reports suggest different compartments, but it seems that class II 
PI3Ks enzymes are predominantly associated with the membrane fraction of cells (Koyasu, 
2003; Vanhaesebroek et al., 2001). 
Class III PI3Ks are homologues of the yeast Vps34p involved in vesicular protein 
sorting. A single class III PI3K catalytic subunit has been identified in all eukaryotic species. 
Both in yeast and mammals, this catalytic subunit exist in a complex with a Ser/Thr protein 
kinase named Vps15p in yeast and p150 in mammals. All eukaryotes appear to have vps34p 
and vps15p analogous. They are highly related enzymes and both display N-terminal 
myristoylation. This lipid modification of Vps15p recruits Vps34p to the membrane in yeast. 
Apparently p150a has a similar role in mammals. In yeast Vps34p/Vps15p heterodimers 
regulate vesicle trafficking trough proteins containing FYVE finger domains that can bind 
PtdIns(3)P. The mammalian ortholog is involved in movement of proteins trough the 
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lysosome. Class III PI3Ks can use only PtdIns as a substrate in vitro, and they are probably 
responsible for the generation of most PtdIns(3)P in cells. Class III PI3Ks are constitutively 
active in vitro, but the regulation their activity in vivo is largely unknown (Vanhansebroek et 
al, 2001; Koyasu, 2003). 
 
1.5. PI3Ks class I – structure, function and regulation 
All enzymes of class I PI3Ks can utilize PtdIns, PtdIns(4)P and PtdIns(4,5)P2 as a 
substrate and produce PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in vitro, respectively. 
Considering that the predominant substrate in cells is PtdIns(4,5)P2, the major product of their 
enzymatic activity in vivo is PtdIns(3,4,5)P3. It is an important lipid second messenger that 
controls a wide range of cellular responses (Figure 1.3.). Resting mammalian cells contain 
significant and constant levels of PtdIns(3)P. While the basal levels of PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 are relatively low, their concentration can rise sharply upon different kinds of 
cellular stimulation. In addition, all lipid substrates and products of PI3Ks are restricted to the 
membrane compartments, and their accessibility appears to be a critical factor for their 
metabolism and function (Vanhaesebroeck et al., 2001).  
PI3K class IA are heterodimers comprised of a catalytic subunit designated as p110 
and a regulatory subunit. There are three different enzymatic subunits of this class named 
p110a, p110b  and p110d, all encoded by different genes. p110a and p110b  are ubiquitously 
expressed while the expression of p110d is largely restricted to the cells of the immune 
system. Class IA enzymes have five different regulatory subunits: p85a, p55a and p50a as 
two splicing variants of the first one, and p85b  and p85g encoded by separate genes. p85a is 
most abundantly expressed (Fruman et al., 1999).  
PI3K class IB is represented by a single heterodimer named PI3Kg. The enzymes 
catalytic subunit known as p110g is predominantly expressed in leukocytes. p110g interacts 
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with a specific type of regulatory subunit, a unique adaptor molecule named p101. This 
regulatory subunit does not have any structural or functional homology to known proteins. 
 
Figure 1.3. Metabolism of phosphoinositides and their functions in cellular 
processes of immune system. Different classes of PI3K phosphorylate 3-position of the 
inositol ring and can utilize different substrates. The amount of PtdIns(3,4,5)P3 is regulated by 
two phosphoinositide phosphatases, SH2 domain-containing 5 inositol phosphatase (SHIP) 
and the tumor suppressor gene product phosphatase and tensin homolog (PTEN).  
PtdIns(4,5)P2 is cleaved by phospholipase C-gamma (PLC-g) providing two distinct second 
messengers: inositol-1,4,5-trisphophate (Ins(1,4,5)P3), which triggers intracellular calcium 
flux, and diacylglycerol (DAG), which acts on PKC enzymes. The phosphorylation on the 4- 
and 5-position of the inositol ring is regulated by distinct phosphoinositide kinases and 
phosphatases. All enzymes that are not discussed in the text are shown in grey letters (after 
Koyasu, 2003). 
 
All four enzymatic subunits of class IA and IB (p110) shares the following homologous 
regions: conserved C-terminus catalytic domain, PIK domain, C2 domain and Ras-binding 
domain (Ras-BD). The catalytic domain of PI3Ks is structurally organized into two lobes. 
The N-terminal lobe contains the nucleotide-binding loop and a conserved lysine residue 
responsible for ATP biding. In many regards this lobe is similar to the corresponding region 
of other protein kinases. The C-terminal lobe, apart from contributing to ATP binding, 
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contains the activation loop that determines the substrate specificity of PI3Ks (reviewed by 
Vanhaesebroeck et al., 2001). Ras-BD is responsible for the interaction of p110 with an 
activated form of the proto-oncogene Ras. The affinity of this interaction is considerably 
lower then the interaction of p110 subunits with their regulatory subunits. The PIK domain is 
a helical domain typical for lipid kinases and it acts as a structural spine around which the 
other domains are anchored. The C2 domain is a protein module with phospholipid binding 
properties and it is involved in the recruitment of the enzymes to the membrane. Class IA 
catalytic subunits contain a N-terminal region responsible for constitutive interaction with 
Class IA regulatory subunits, while the corresponding region of PI3Kg facilitates interaction 
with p101.  
Isoforms of class IA subunit p110 do not seem to have binding specificity for distinct 
regulatory subunits (Vanhaesebroeck et al., 1995). For the regulatory subunits of class IA 
distinct domains are known, two Src homology domain 2 (SH2) domains separated by ‘inter 
SH2 domain’ which is responsible for constitutive interaction with the catalytic subunits of 
class IA, and it was proved that regulatory subunits stabilize the unstable p110 catalytic 
subunits (Yu et al., 1998; Vanhaesebroeck et al., 2005). The two SH2 domains can mediate 
interaction with tyrosine-phosphorylated proteins, which appears to be critical for recruitment 
of p110 subunits to the inner surface of the plasmamembrane, the location of their lipid 
substrate. This translocation also brings the catalytic subunit in the vicinity of 
phosphotyrosine residues in receptors, adaptor proteins and other molecules.  
Besides translocation, the activation of catalytic subunits of class IA enzymes is closely 
connected to activation of tyrosine-kinase-associated receptors. How this activation is 
achieved is still not fully elucidated (Okkenhaug and Vanhaesebroeck, 2003a). Activation of 
PI3K class IA by Ras is well documented. This interaction elevates lipid-kinase activity of 
PI3K class IA above the level induced by phosphotyrosin engagement of their regulatory 
subunits (Rodrigez-Vinciana et al., 1994, 1996). There are reports that GPCR ligands can also 
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stimulate protein members of PI3K Class IA. Such kind of up-regulation was observed in cell 
lines that do not express detectable levels of PI3Kg and it seemed to be related mostly to the 
b-isoform of PI3K (reviewed by Vanhaesebroeck and Waterfield, 1999).   
 
Figure 1.4. Schematic presentation of functional domains found in different PI3K 
family members. All enzymatic subunits of PI3Ks contain the highly conserved catalytic 
domain and the C2 domain, which is involved in recruiting PI3K to membrane. These two 
domains are connected by a helical domain (PIK). In addition, both class I and II enzymes, 
contain a Ras-binding domain (Ras-BD). All regulatory subunits of class IA contain dual SH2 
domains connected with an inter-SH2 domain. The two SH2 domains bind to tyrosine-
phosphorylated peptide motifs, leading to activation of p110 subunits. The inter-SH2 domain 
constitutively interacts with the N-terminal domain of p110 a, b, d in order to maintain the 
stability of p110 in the cell. p85a and p85b have on their N-terminus an Src homology 
domain 3 (SH3), a Brc homology domain (BH) and an additional proline–rich region (Pr), the 
functions of which are not fully understood. p101, the regulatory subunit of class IB, 
specifically interacts with the N-terminal domain of p110g. The Phox homology domain (PX), 
found only in the class II PI3K family, binds PI(3)P and PI(3,4)P2 and may recruit class II 
PI3Ks to the membrane. Vps34 forms a heterodimer with the serine/threonine kinase Vps15p 
and regulates vesicle trafficking (after Koyasu, 2003).  
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 The enzymatic activity of PI3Kg is primarily regulated by G protein-coupled receptors 
(GPCR) (Stoyanova et al., 1995). The Gbg subunit of the G-protein mediates activation of 
PI3Kg and directly activates PI3Kg in vitro. Both subunits of PI3Kg have been shown to bind 
Gbg in vitro, but p101 does so with a five-fold higher affinity (Stephens et al., 1997; Voigt et 
al., 2005). p101 binds to Gbg released from heterotrimeric GPCR and recruits the p110g to 
the plasmamembrane, which is a prerequisite for the GPCR-induced PI3Kg activation in vivo 
(Brock et al., 2003). An N-terminal domain of p101 mediates heterodimerisation with p110g, 
whereas the C-terminal domain of p101 is responsible for the interaction with Gbg (Voigt et 
al., 2005). p101 appears to be essential for Gbg-mediated activation of PI3Kg in living cells, 
but surprisingly, the lipid-kinase activity of PI3Kg can be stimulated by Gbg in the absence of 
p101 (Leopoldt et al., 1998). PI3Kg, like the PI3K class IA, also interacts with Ras in a GTP-
dependent manner. (Rodriguez-Viciana et al., 1994; Rubio et al., 1997; Vanhaesebroeck et al., 
1997). Ras forms a transient complex with PI3Kg and activates it in vivo and in vitro. 
Moreover, conformational changes of PI3Kg induced by Ras binding implicate that allosteric 
mechanism, in addition to membrane recruitment, may be important for the activation of 
PI3Ks (Suire et al., 2002; Pacold et al., 2000).  
The major downstream targets of lipid-kinase activity of PI3Ks are the proteins with 
Plekstrin Homology (PH) domain. PH domains are globular protein domains of about 120 
amino acids that can bind phospholipids, although some PH domains can mediate protein-
protein interactions (Vanhaesebroeck and Waterfield, 1999). Many, if not most PH domains, 
bind PtdIns(3,4,5)P3 with high affinity. PH domains have been identified in all eukaryotes in 
about 200 different proteins including kinases, phospholipases, structural proteins, nucleotide-
exchange factors and adaptor proteins (Vanhaesebroeck & Waterfield, 1999; Sasaki et al., 
2002). In most of the cases it is proved that phospholipid binding affects localisation, 
conformation and/or activity of these proteins (Sasaki et al., 2002). The most important 
known targets of PI3Ks enzymatic activity are two serin/threonin kinases: Phosphoinositide-
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dependent kinase 1 (PDK1) and Protein Kinase B (PKB) also known as Akt. PDK1 is 
important and/or essential for activation of many signalling proteins such as Protein Kinase A 
(PKA) (Cheng et al., 1998), Protein Kinase B (reviewed by Vanhaesebroeck and Waterfield, 
1999), Protein Kinase C (PKC) isoforms (Le Good et al., 1998; Chou et al., 1998), serum- 
and glucocorticoid-iduced protein kinase (SGK) (Park et al., 1999; Kobayashi and Cohen, 
1999) and p70S6 and p90S6 kinases (Pullen et al., 1998). After translocation to the membrane 
PKB/Akt is phosphorylated by PDK1 on Thr308 and subsequently within its hydrophobic 
motif on Ser473 by kinases dubbed ‘PDK2’ which leads PKB/Akt to full activation. Although 
several proteins have been proposed to act as PDK2, the enzyme with this function has not 
been identified so far. The PI3K-PDK1-PKB/Akt signalling cascade is in the focus of many 
authors as the one of the most relevant anti-apoptotic pathways. PKB/Akt–mediated 
regulation of forkhead transcription factors (FOXO) and cyclin D1 allows cell cycle entry, 
while phosphorylation of IkB kinase (IkBK) and of proteins of the cell-death machinery such 
as BAD and caspase-9 inhibits their activity and promotes cell survival (Wymman & Marone, 
2005). In addition, PKB/Akt plays an important role in the insulin signalling and activation of 
endothelial nitric oxide synthetase (eNOS) (reviewed by Vanhaesebroeck & Waterfield, 
1999).  
The aforementioned members of the protein kinase C (PKC) family also require 
phosphorylation within their activation loop by PDK1 (reviewed by Sasaki et al., 2002). This 
phosphorylation is only a priming step in the autophosphorylation required to generate a 
catalytically competent form of PKC that needs diacylglycerol binding and/or relief from 
autoinhibition for full activation (Parekh et al., 2000a). Their binding to PDK1 also suggests a 
potential role of PDK1 in regulation of PKCs subcellular localisation (Ward & Catrell, 2001). 
The other targets of PI3Ks lipid kinase activity are tyrosine kinases of Tec family, 
Bruton tyrosine kinase (BTK) and Inducible T cell kinase (Itk), enzymes indispensable for 
normal development and function of B and T lymphocytes, respectively. Presence of PH 
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domains and PtdIns(3,4,5)P3-dependent activity are also confirmed for some GTP/GDP 
exchange factors (GEFs) and GTPase-activating proteins (GAPs), e.g. GTPases of the Rho, 
Ras and Arf families. Examples for this are GEFs specific for the Rho family of GTPases 
(Rho, Rac and cdc42). It has been proved that Rac is activated during chemotaxis stimulated 
by tyrosine kinases in a PI3K-dependent manner (Han et al., 1998). 
Different PI3K catalytic subunits of class IA and IB exhibit dual specificity both as 
lipid kinases and protein serine kinases. All PI3K class I enzymes have one single catalytic 
centre responsible for both kinase activities. Their protein kinase activity is directed towards 
auto-phosphorylation and/or phosphorylation of their regulatory subunits. This kind of 
enzymatic activity has been demonstrated in vitro, but no other proteins were identified as a 
substrate of these enzymes in vivo so far. Hence, the protein kinase activity of p110a is 
directed toward phosphorylation of p85 adaptor protein, whereas p110d is selective for an 
autophosphorylation site (Ward and Cantrell, 2001). It has been shown that PI3Kg protein 
kinase activity can activate a mitogen activated protein kinase (MAPK) in a transient 
transfection system. In this study authors used a PI3Kg mutant without lipid kinase activity 
but with retained protein kinase activity (Bondeva et al., 1998). It is possible that different 
protein kinase activities may give unique cellular functions to different PI3K isoforms. 
Two phophosphoinositide phosphatases are major negative regulators of PI3Ks lipid 
kinase activity – phosphatase and tensin homologue (PTEN) and haematopoietic-specific 
SH2-domain containing inositol 5-phosphatases (SHIP). PTEN cleaves the phosphate from 
the 3-position of PtdIns(3,4,5)P3 generating PtdIns(4,5)P2 and in this way counteracts all 
PI3Ks. PTEN is a tumour suppressor that is often inactivated in different types of cancer, 
leading to the constitutive activation of the class I PI3K-signaling pathways. On the other 
hand, SHIP removes phosphate group from the 5-position of PtdIns(3,4,5)P3 and converts it to 
PtdIns(3,4)P2. Members of the SHIP phosphatases have inhibitory role in the immune system 
and, probably, in insulin signalling. SHIP mediates an important negative feedback 
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mechanism in lymphocytes. Loss of SHIP results in an unbalanced immune response 
(reviewed by Ward & Cantrell, 2001). Furthermore, phospholipase Cg (PLCg) cleaves 
PtdIns(4,5)P2 creating two important second messengers: inositol-1,4,5-phosphate and 
diacylglycerole. PLCg does not directly counteract the activity of PI3K, but it reduces the 
amount of the major PI3K substrate. 
Two unrelated pharmacological inhibitors of PI3Ks, Wortmannin and LY294002, 
were highly useful research tools for proving the involvement of PI3Ks in many signalling 
events. Both substances are cell-permeable, low-molecular-weight compounds, which are, at 
relatively low doses, specific inhibitors of most  PI3Ks. Unlike LY294002, Wortmannin binds 
irreversibly to the PI3K ATP binding pocket of the catalytic subunit, a reaction that has been 
competed by ATP and PtdIns(4,5)P2 but not PtdIns (Wymann et al., 1996). LY294002 is a 
competitive inhibitor of the ATP binding site. Wortmannin is usually applied at final 
concentrations of 20-100 nM while concentrations of LY294002 is in the range of 5-30 µM. It 
must be mentioned that Wortmannin, in contrast to LY294002, is rather unstable in aqueous 
solutions and also has a tendency to react with serum proteins, which makes it inappropriate 
for treatment of the cell culture for periods longer then few hours (Vanhaesebroeck & 
Waterfield, 1999). All mammalian class I, II and III PI3K members show a similar in vitro 
sensitivity to Wortmannin and LY294002 (Ward et al., 1996, Vanhaesebroeck & Waterfield, 
1999). Moreover, both compounds have serious inhibitory activity on numerous cellular 
functions resulting in their high cytotoxicity. For example, pharmacological inhibitors of 
PI3Ks block or severely compromise development and functions of the cells of the immune 
system. The first studies in vivo conducted by Gunther et al., in 1989 (reviewed by 
Okkenhaug and Vanhaesebroeck, 2003) already indicated a high potential of Wortmannin as 
an immune suppressor but also its high toxicity. Wortmannin and LY294002 were therefore 
never considered as potential therapeutic substances. 
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1.6. Phosphoinositide 3-kinases in the immune system 
Activation of tyrosine-kinase-related receptors in the cells of the immune system is 
known to activate class IA PI3Ks. For example, cytokines such as interleukin 2 (IL-2), IL-3, 
IL-6, IL-7, IL-15, granulocyte colony-stimulating factor, erythropoietin, oncostatin M and 
interferons activate class IA PI3Ks in many types of immune cells. In addition, cytokine 
receptors with intrinsic tyrosine-kinase activity (macrophage colony-stimulating factor 
receptor and c-Kit) can also activate class IA PI3Ks. Finally, these enzymes are known to be 
activated upon antigen recognition by B cell receptor (BCR) and TCR (Koyasu, 2003).  
On the other hand, several lines of evidence indicate that PI3Kg, the only member of 
class IB PI3K, is involved in chemokine-induced cell migration of different immune cells. For 
example, binding of interleukin 8 (IL-8 or CXCL1) and stromal-cell-derived factor 1 (SDF1 
or CXCL12) to their specific receptors, which are GPCR, induce wortmannin-sensitive 
chemotaxis of neutrophils and T cells, respectively (reviewed by Curnock et al., 2002).   
The established pharmacological inhibitors of PI3Ks are highly toxic, and do not 
discriminate between different isoforms of PI3Ks. Therefore, alternative approaches were 
applied in order to investigate the involvement of PI3Ks in the regulation of immune 
functions. Different experimental designs, many of them including overexpression of mutant 
PI3K subunits in different cell models, gave rise to conflicting, and sometimes opposite 
results. The examples of such controversies are the recruitment/activation of PI3Ks after 
CD28 ligation in T cells or the impact of wortmannin and LY294002 on T cell activation. 
Pharmacological inhibitors of PI3Ks clearly inhibit activation of primary T cells, but in many 
regards they are considered equally ineffective on certain transformed T cell lines, especially 
on Jurkat cells (reviewed by Kane & Weiss, 2003). A similar situation emerged around the 
involvement of PI3K in IL-2 production upon T cell activation. The first clear evidence of 
PI3K involvement in IL-2 expression in activated T cells came from Eder et al. (1998). The 
authors came to the conclusion that class IA PI3K has an essential role in T cell receptor-
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mediated IL-2 gene expression in normal T cells, as the authors state in the title of their 
manuscript. 
The abovementioned controversies required the application of a new approach to 
investigate PI3Ks involvement in the regulation of immune functions in vivo, so gene 
targeting seemed to be the next reasonable step. 
 
1.6.1. Targeting the p85a  subunit of class IA 
p110a and p110b  knockout mice ware generated and both KO died in utero between 
embryonic days 9,5 and 10,5 or shortly after embryo implantation, respectively. Double 
heterozygous P110a+/-p110b+/- mice grew normally, which suggests that both isoforms have 
distinct roles in foetal development (Bi et al., 1999, 2002). Thus, the effect of these mutations 
on immune cells could not be determined. The alternative approach was to target the 
regulatory subunit of Class IA PI3Ks.  
Two groups independently created p85a KO mice using different approaches. Suzuki 
et al. (1999) deleted the first exon of the gene, so the p55a and p50a splicing isophormes 
were retained; these animals were viable. On the other side, Fruman et al. (1999a) disrupted 
the expression of all three variants. The mice generated in such manner died shortly after 
birth. Fruman et al. (1999a) therefore used a RAG (recombination-activating gene) 
complementary approach to investigate function of lymphocytes in their model. The results of 
those two groups are mostly consistent. Both groups could not find any remarkable defect in 
T cell development or functions. In contrast to that, B cell development and functions were 
seriously compromised: transition from pro-B to B cell was partly blocked resulting in 50-
80% reduction in the number of mature B cells, and reduction or absence of peritoneal CD5+ 
B-1 cells. Proliferation induced by activating B cell receptor (BCR) or anti-CD40 activation 
was impaired. However, Fruman et al. (1999a) reported that the proliferative response to anti-
CD40 activation can be rescued with interleukin-4 (IL-4) costimulation. T cell-dependent, but 
not T cell-independent antibody production was also impaired. Finally, further investigation 
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by both groups described reduced expression of all catalytic subunits of class IA and increased 
expression of p85b . Mast cells of those mice exhibited reduced SCF- or IL-3-induced 
proliferation, moderately reduced number of tissue mast cells and complete absence of 
gastrointestinal mast cells, while dendritic cells showed increased IL-12 production and 
reduced sensitivity to Leishmania major infection (reviewed by Vanhaesebroeck et al., 2005). 
Conflicting data about alterations in some specific signalling pathways imply that these p85 
KO mice cannot be considered as PI3K knockouts (Okkenhaug & Vanhaesebroeck, 2003). 
P85b  knockout mice are viable and do not have any apparent defect in the immune 
system (Ueki et al., 2003). Targeting of the gene encoding p55g has not been reported so far. 
 
1.6.2. Targeting the p110 subunits of class IA 
p110d knock-out mice have been generated and they are viable (Clayton et al., 2002). 
Nevertheless, the most valuable data about the role of p110d in immune system are coming 
from the group of Vanhaesebroeck who applied a more elegant strategy: instead of deleting 
the whole gene they introduced a point mutation creating a knock-in (KI) mouse line that 
expresses a kinase-dead enzyme. This method avoids disturbing the molecular balance of 
different PI3K isoforms (Okkenhaug et al., 2002). The phenotype of this mouse named 
p110bD910A/D910A is reviewed in detail by Okkenhaug and Vanhaesebroeck (2003). In p110d 
KO mice expression of the regulatory class IA subunits was reduced in B cells, whereas, in 
p110d KI cells p85, p55 and p50 levels were not altered. The phenotypes of p110d KO and KI 
mice were similar with respect to signalling and functional defects in lymphocytes, although 
they were not directly compared. Briefly, those phenotypes in many regards resemble the 
phenotype of p85a KO mice, at least regarding the B cells: both p110d KO and KI exhibited a 
nearly 50% reduction in the number of B cells in the spleen, anti-IgM-induced Akt/PKB 
activation was almost completely lost and calcium influx was attenuated. Further, BCR 
induced activation and proliferation was impaired, just like anti-CD40 and IL4 induced 
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proliferation of B cells. In addition, both T cell-independent, as well as T cell-dependent 
antibody production was impaired as a consequence of their impaired T cell functions.  
The phenotype of T cells also revealed interesting facts: Akt/PKB activation upon 
anti-CD3 activation of the p110dD910A/D910A T cells was almost ablated, calcium flux was 
attenuated, the number of T cells in the spleen reduced, and mature T cells had a more ‘naive’ 
phenotype. However, the size and cellularity of the thymus was comparable to those in the 
WT mice. Moreover, it was possible to rescue reduced anti-CD3-induced proliferation with 
anti-CD28 costimulation, while cytokine production remained normal. Mutation of p110d 
also induced minor functional defects in mast cells, and possibly in neutrophils 
(Vanhaesebroeck et al., 2005). An important finding in p110d KI mouse was the differential 
sensitivity of different receptor systems to p110d inactivation. This indicated that p110d 
selectively couples to specific receptor systems (Vanhaesebroeck et al., 2005). Further 
supported with some additional results, above-mentioned authors believe that the p110d 
isoform is the major provider of PI3K activity downstream of BCR and TCR. 
 
1.6.3. PI3Kg and immune system 
Three groups at approximately same time generated PI3Kg knockout mice by using 
different strategies (Li et al., 2000; Sasaki et al., 2000; Hirsch et al., 2000). All mice were 
viable, fertile and displayed normal life span in standard conditions. The focus of those 
preliminary investigations was mainly on the haematopoietic cells. There was no apparent 
effect of this deletion on B cell development and function, except that the production of 
antibodies containing the lambda light chains in response to T cell-independent antigens were 
altered (Li et al., 2000). However, the main phenotype of PI3Kg KO mice is mostly related to 
the cells of the innate immune system. Although the total number of neutrophils of PI3Kg KO 
mice increased, they exhibited reduced chemotaxis both in vivo and in vitro. Accumulation of 
neutrophils in the peritoneal cavities was significantly reduced in both casein- and Listeria 
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monocytogenes-treated KO mice in comparison to control animals. In vitro chemotaxis 
induced by GPCR agonists (N-formil-Met-Leu-Phe (fMLP) and C5a) of PI3Kg-/- neutrophils 
was reduced by 70%. The results indicated that observed reduction in chemotaxis was caused 
by impaired motility and not by altered adhesion of the cells. In addition, the GPCR-induced 
respiratory burst was reduced in freshly isolated bone marrow neutrophils from PI3Kg KO 
mice (Sasaki et al. 2000; Li et al., 2000; Hirsch et al., 2000). Macrophages of PI3Kg KO mice 
had chemotaxis reduced by 52-85%; it was induced by different GPCR agonists such as: 
RANTES (Regulated on Activation, Normal T cell Expressed and Secreted), macrophage 
inflammatory protein-5 (MIP-5), macrophage derived chemokine (MDC), stromal cell 
derived factor-1 (SDF-1) and C5a in vitro. Interestingly, PI3Kg-/- peritoneal macrophages also 
exhibited reduction of chemotaxis by 85% toward vascular endothelial growth factor (VEGF), 
an agonist known to bind to the receptor tyrosine-kinase. Moreover, PI3Kg KO mice had 
impaired inflammatory response to septic peritonitis: 12 h after bacteria injection the number 
of peritoneal PI3Kg-/- macrophages was reduced by 90% in comparison to the WT. 48 h after 
intraperitoneal injection of Staphylococcus aureus, there were ten-fold more bacteria in PI3Kg 
KO mice peritoneum, in spite of the fact that PI3Kg-/- macrophages did normally phagocytose 
bacteria (Hirsch et al., 2000). PI3Kg was also proved to positively regulate SDF1-induced T 
cell migration both in a cell line model (Curnock et al., 2002) and in in vitro assays with 
mouse T cells (Reif at al., 2004). PI3Kg-/- bone marrow derived mast cells were less sensitive 
to antigen-IgE stimulation than WT mast cells. The release of the histamine-containing 
granules and the rise of the intracellular calcium concentration were also diminished in PI3Kg-
/- mast cells (Sasaki et al., 2000; Laffargue et al., 2002). In vivo and ex vivo migration of 
dendritic cells was also reported to be reduced in PI3Kg KO mice (Del Prete et al., 2004).  
One of the most intriguing features of PI3Kg KO mice seems to be the phenotype of 
their T cells. PI3Kg KO mice had reduced thymic cellularity and a reduced size of the thymus 
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itself. Thymocytes exhibited enhanced apoptosis when stimulated with anti-CD3e antibody in 
vivo, or in combination with adenosine analogues. The KO mice thymocytes also showed a 
defect in the proliferative expansion that accompanies development from the double negative 
(DN) to the double positive (DP) stage (Sasaki et al., 2000). Later findings confirmed that 
PI3Kg modulates T cell differentiation at several stages. PI3Kg deficiency moderately impairs 
pre-TCR-induced DN thymocytes differentiation - PI3Kg KO mice showed an increase in DN 
cell numbers. The lack of PI3Kg affected CD4/CD8 lineage commitment during positive 
selection and augmented CD8 cell differentiation. In addition to this effects, it was confirmed 
that the lack of PI3Kg reduced the migration of mature thymocytes to the periphery 
(Rodriguez-Bolardo et al., 2003).  
Sasaki et al. (2000) also reported that PI3Kg KO mice had a reduced number of CD4 T 
cells, but no CD8 T cells in spleen, and a normal ratio of different T cell sub-types in other 
peripheral lymphoid organs. The response of the mature PI3Kg-/- T cells to activation by 
phorbol ester and Ca2+ ionophore (TPA/Ionomycin) was normal, while proliferation induced 
by anti-CD3 antibody and concanavalin A (Con A) was impaired. A functional defect in 
interleukin 2 (IL-2) and interferon gamma (INF-g) production upon activation was more 
pronounced after TCR-induced activation. It was possible to rescue impaired TCR-induced 
proliferation with anti-CD28 costimulation, unlike activation-induced cytokine production. 
CD8+ T cell-dependent antiviral response and functional T helper cell-dependent response to 
hapten antigens in vivo were impaired as well (Sasaki et al., 2000). 
PI3Kg knock-in mice which express full length kinase-dead enzyme have been 
generated and compared to the PI3Kg KO mice (Patruccio et al., 2004). Although these mice 
had a similar defect in immune cells, they displayed important differences in their cardiac 
phenotype. PI3Kg seems to be the part of the protein complex? which is indispensable for the 
proper function of the phosphodiesterase 3B (PDE3B). This enzyme degrades cAMP, and the 
loss or deregulation of PDE3B activity in cardiac cells upon PI3Kg KO resulted in increased 
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cAMP levels, leading to an activation of protein kinase A and an increased heart contractility. 
This effect was absent in PI3Kg KI mice, which indicates that this particular role of PI3Kg is 
not related to its kinase activity but to the proposed scaffolding function of this protein. This 
is an example of how different gene-silencing approaches can lead to different functional 
outcomes with important implications for understanding of enzyme functions and also for 
their potential use as pharmacological targets (Vanhaesebroeck et al., 2005).  
Ever since the first experiments with PI3Kg KO mice it became obvious that this 
enzyme, along with the PI3Kd isoform, may become a very promising drug target (Wetzker 
and Romel, 2004). First, both KOs are viable and fertile and without proved physiological 
disturbances as long as their immune systems are not challenged. Second, both isoforms are 
predominantly expressed in the cells of the immune system and both enzymes play important 
roles in functions of those cells. Moreover, PI3Kg is biochemically distinct from the class IA 
PI3K (Vanhaesebroeck et al., 2005) and its crystal structure is determined (Walker et al., 
2000; Pacold et al., 2000). Finally, PI3Kg is doubted to be one of the key modulators in 
inflammation and allergy (Wymann et al., 2003).  
Indeed, in the last couple of years Serono Pharmaceutical Research institute (Serono 
International, Geneva, Switzerland) in cooperation with several academic research groups 
designed and developed a series of chemical substances which are potent and selective 
PI3Kg inhibitors (Camps et al., 2005). All designed substances are small-molecule ATP 
analogues with high cellular permeability. Some of those substances exhibit a high inhibitory 
potency toward PI3Kg, while maintaining a favourable selectivity profile against other 
PI3K isoforms, as well as against a broad range of tyrosine and serine-threonine protein 
kinases. The compound named AS-605240 was found to be the most superior PI3Kg inhibitor 
with improved biopharmaceutical profile, and it was able to mimic the effect of PI3Kg 
deficiency in the whole panel of in vivo and in vitro assays. The same substance was also 
successfully applied per os to the experimental animals, and this treatment suppressed the 
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progression of joint inflammation and damage in two distinct mouse models of rheumatoid 
arthritis (Camps et al., 2005). The oral application of AS-605240 was also successful in the 
case of MRL-Ipr mice, a mouse model of human systemic lupus erythematosus (SLE), a 
chronic inflammation caused by deregulation of T cell-mediated B cell activation resulting in 
glomerulonephritis and renal failure. The treatment reduced the glomerulonephritis and 
prolonged the lifespan of the animals, proving again that PI3Kg may be a useful target in the 
treatment of chronic inflammations (Barber et al., 2005). 
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1.7. Aim of this work 
 
PI3Ks are important signal mediators involved in the regulation of diverse biological 
functions, including cell growth, differentiation, survival, proliferation, migration and 
metabolism. PI3Ks are indispensable for the development and proper functions of T 
lymphocytes and other cells of the immune system. The involvement of PI3Ks in the 
activation and proliferation of T cells was mostly related to the PI3K class IA enzymes, but the 
mechanism of this involvement is still elusive. Ever since PI3Kg KO mice have bin generated 
(Li et al., 2000; Sasaki et al., 2000; Hirsch et al., 2000), many convincing evidences emerged 
about the involvement of the PI3Kg, the single member of class IB PI3K, in T cell activation, 
proliferation and cytokine production.  
It was proved  that PI3Kg-/- mice had disrupted tymic development, reduced number of 
thymocytes and of CD4 T cells in spleen (Sasaki et al., 2000; Rodriguez-Bolardo et al. 2003). 
PI3Kg-/- T lymphocytes exhibited impaired TCR-induced proliferation and subsequent 
cytokine production in vitro. It was possible to rescue impaired proliferation of PI3Kg-/- T 
cells by the activation with Ionomycin and phorbol ester, but not the cytokine production. 
Moreover, CD8 T cell-dependent antiviral response as well as functional T helper cell-
dependent response were impaired in vivo (Sasaki et al., 2000). 
In work presented here we analysed the profile of T cells of PI3Kg-/- mice in more 
details and tried to elucidate if their impaired TCR-induced IL-2 production is one of the 
major causes of  reduced proliferation of PI3Kg-/- T cells. 
In order to reveal new details about involvement of PI3Kg in TCR-induced activation 
and subsequent IL-2 production of the T cells, we used AS041164, a specific pharmacological 
inhibitor of PI3Kg. In our experiments we used the Jurkat cell line, the most commonly used 
model of human T cells. Specific features of this cell line in respect to the regulation of PI3Ks 
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activity made it possible to elucidate whether lipid-kinase or protein-kinase activity of PI3Kg 
is important for the analysed processes. 
In order to find out more about the TCR signalling mechanism which involves PI3Kg, 
we tried to identify interacting partners of PI3Kg in Jurkat cells. The focus of our attention 
were proteins whose interaction with PI3Kg is regulated by T cell receptor activation, and 
which are relevant for the cellular functions of the T cells at the same time. 
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2. Results 
 
2.1. Thymocytes and T cells of PI3Kg  KO mice  
The PI3Kg knock-out (KO) mice, used as a model in our study, were generated as 
described by Hirsch et al. (2000). It was proved that PI3Kg-/- T cells have altered thymic 
development, impaired TCR-induced proliferation and diminished subsequent cytokine 
production (Rodriguez-Bolardo et al., 2003; Sasaki et al., 2000). In order to analyse in more 
details the role of PI3Kg in T cells, we thoroughly investigated the total number of PI3Kg-/- T 
cells and thymocytes in lymphoid organs, as well as the ratio of different cellular 
subpopulations. 
 
 Figure 2.1. The total number of cells in spleen, lymph nodes and thymus. The 
organs were homogenised to a single cell suspension, and the cells were counted using the 
Neubauer counting chamber. Tripan-blue exclusion was used to confirm cell viability and 
only viable cells were taken into account. No significant differences in percentage of viable 
cells between different samples were observed.  
 
The cell analyses were performed on two occasions with seven KO and seven wild-
type (WT) animals in total, all between two and five months of age. All the animals were fit, 
healthy and the KO animals were without any apparent morphological and morphometrical 
deviation. The total cell number of thymus, spleen and lymph nodes was determined after the 
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examined organs had been homogenized to a single cell suspension. The percentage and 
number of T cells in total and different T cell subpopulation, as well as different thymocytes 
subpopulations was examined by flow cytometry.  The results revealed that in all examined 
peripheral lymphoid organs of PI3Kg KO mice the total number of T cells was reduced by 
about 50% or more (Figure 2.1.). The size of thymus and spleen in KO mice was reduced 
approximately by 30-50% in comparison to the corresponding organs of WT mice exhibiting 
much softer consistence. Lymph nodes of PI3Kg KO mice were significantly reduced in size 
as well, and difficult to visualize in the majority of cases.  
A  
B  
Figure 2.2. A) The total number of all T cell (CD3+), CD8+ and CD4+ T cells in 
spleen, cell number in millions. B) The ratio of  T cell, CD8+ and CD4+ T cells in spleen, 
results given as percentage of all spleenocytes. Analysis performed by flow cytometry upon 
staining with specific antibodies; subpopulations of the T cells were identified as double 
positive cells (CD4+/bTCR or CD8+/bTCR). 
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Number of T cells in spleen of PI3Kg KO mice was reduced to almost one third in 
comparison to the WT (Figure 2.2). Cell number of both subpopulations of mature T cells 
(CD4+ and CD8+) contributed to this difference. Comparison of percentages of different T 
cell populations in the KO and WT spleen shows slightly reduced percentage of both major 
subpopulations (CD4+ and CD8+) in PI3Kg KO as well. These results are in slight 
discrepancy with previous finding by Sasaki et al. (2000), who observed only reduction of 
CD4+ T cells in the spleen. 
A  
B  
Figure 2.3. A) The total number of all T cell (CD3+), CD8+ and CD4+ T cells in 
lymph nodes, cell number in millions. B) The ratio of all T cell (CD3+), CD8+ and CD4+ 
T cells in lymph nodes, results given as percentage of all cells from the lymph nodes. 
Analysis performed by flow cytometry upon staining with specific antibodies; subpopulations 
of the T cells were positively identified as cells positive for double staining (CD4+/bTCR or 
CD8+/bTCR). 
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The cell number reduction in the PI3Kg KO lymph nodes was severe – WT animals 
had nearly four-fold more T cells (Figure 2.3). The ratio between of CD4+ and CD8+ T cells 
in the lymph nodes of PI3Kg KO mice showed nearly no differences to the WT. Again, such 
effect was not described by Sasaki et al. (2000). 
A  
B  
Figure 2.4. A) The total number of single positive (CD8+ and CD4+), double 
positive (DP, CD4+/CD8+) and double negative (DN, CD4-/CD8-) thymocytes, cell 
numbers in million. B) The ratio of single positive, double positive and double negative 
thymocytes, results given as percentage of all thymocytes. Analysis performed by flow 
cytometry upon staining with specific antibodies.  
 
The total number of thymocytes in KO was nearly half of the number of WT 
thymocytes and this difference was mostly caused by reduction of double-positive cells 
(Figure 2.4) which, by default, represent the major subpopulations of thymocytes. Small 
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reduction in number of single-positive cells could also be observed. There were no striking 
differences in the ratio of major thymocyte subpopulations (CD4+, CD8+, double positive – 
DP and double negative – DN) in WT and KO. A relatively small decrease in percentage of 
DP and a small increase in percentage of DN and CD8+ thymocytes were observed.  
Our results about the number of PI3Kg-/- thymocytes proved involvement of PI3Kg in 
positive regulation of thymic growth and T cell differentiation in thymus and in many regards 
confirmed earlier findings by Sasaki et al. (2000) and Rodrigues-Bolardo et al. (2003). In 
contrast to these earlier findings, we observed stronger reduction of mature T cells number in 
all peripheral lymphoid organs of PI3Kg KO mice, and both major subpopulations of mature 
T cells were affected. This appears to be a consequence of impaired development and 
differentiation of PI3Kg-/- thymocytes.   
Additional flow cytometry analyses included number/ratio of cells positive for gdTCR, 
CD44, CD45RB, CD62L and CD25 (data not shown). With exception of the reduced total 
number in peripheral lymphoid organs, ratio of different subpopulations of resting mature 
PI3Kg-/- T cells did not exhibit any significant difference in comparison to the WT T cells. 
 
2.2. Activation and proliferation of PI3Kg -/- T cells 
Further more, we investigated proliferation of PI3Kg-/- T cells purified from the spleen 
by negative depletion. At first, in order to examine the ability of PI3Kg-/- T cell to proliferate, 
the cells were activated by different mitogens. The proliferation was measured as a 
[3H]thymidine uptake 72 h upon the activation. A smaller number of samples (from two KO 
and two WT mice) were activated with phytohemagglutinin (PHA), lipopolysaccharides 
(LPS), Concavalin A (Con A) and Ionomycin + phorbol ester (IONO+TPA). These 
substances are commonly used as positive controls for the activation of lymphocytes because 
of their wide-range none-specific activating effect. These experiments did not show any 
significant differences in proliferation between PI3Kg-/- and WT T cells (data not shown). 
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TCR-induced (anti-CD3-induced) proliferation was also performed. PI3Kg-/- T cells exhibited 
approximately 30% reduced anti-CD3-induced proliferation (Figure 2.5.A), which represents 
a weaker reduction than observed by Sasaki et al. (2000). We also confirmed previous 
findings by the same authors that impaired proliferation of PI3Kg-/- T cells can be rescued by 
anti-CD28 costimulation (data not shown).  
A  
B  
Figure 2.5. A) TCR-induced proliferation of T cells purified from spleen. B) 
TCR-induced proliferation of T-cells purified from spleen, +/- IL-2 costimulation (5 
ng/ml of human recombinant IL-2 where indicated). The activation of T cells was done 
with anti-CD3 antibody immobilised on the solid surface using indicated concentrations. 
Proliferation was measured by [3H]-thymidine uptake and results are given as counts per 
minute (cpm). The results represent readouts from one of the two independent experiments 
which show the same trends. In both types of experiments samples from at least 3 WT and 3 
KO animals were used. 
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In order to elucidate if the reduced cytokine production upon activation can be the 
cause of impaired anti-CD3-induced proliferation of PI3Kg-/- T cells, we activated T cells 
from the KO and WT mice with and without IL-2 costimulation. Indeed, recombinant IL-2 
enhanced anti-CD3-induced proliferation both in KO and WT T cells and rescued 
proliferation of PI3Kg-/- T cells (Figure 2.5B).  
Proliferation of PI3Kg-/- T cells activated with different mitogens was comparable with 
proliferation of WT T lymphocytes, while PI3Kg-/- T cells activated trough TCR exhibited 
reduced proliferation. This clearly indicated involvement of PI3Kg in some of the signalling 
pathways emerging from activated TCR. Moreover, IL-2 costimulation was able to rescue 
impaired proliferation of PI3Kg-/- T cells. Considering that reduced cytokine production of 
KO T lymphocytes upon TCR-induced activation is caused by the absence of PI3Kg (Sasaki 
et al., 2000), our results implicate that the lack of cytokines, especially IL-2, may be the 
major cause of PI3Kg-/- T cell functional defect. 
 
2.3. Inhibitory potential and selectivity of AS041164, a specific inhibitor of PI3Kg  
In order to elucidate how PI3Kg couples the activation of TCR and IL-2 production we 
took the opportunity to use the PI3Kg specific inhibitor AS041164. This substance is one 
from the series of complex compounds developed by SERONO (Geneva, Switzerland) and it 
was kindly provided by this company. The AS041164 binds non-covalently and reversibly to 
PI3Kg ATP-binding site and blocks its kinase activity. The substance is a derivate of 
hiadolizine-2,4-dione with molecular weight of 249,24. The AS041164, as well as other 
substances from the same series, does not show notable activity against a wide panel of 
protein kinases at low µM concentration. The AS041164 does not exhibit high selectivity: in 
vitro it shows nearly four times higher affinity to bind to PI3Kg than PI3Ka  (unpublished 
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data, SERONO Company). In our experiments the AS041164 was applied in the range of 
concentration between 3 µM and 30 µM according to the manufacturer’s recommendations.  
Possible cytotoxicity of AS041164 was tested in our system. We used Jurkat cell line 
as the most commonly used model of human T cells. The cells were grown in the standard 
conditions and the impact of AS041164 on the cell proliferation and viability was examined 
after 24 and 48 hours of treatment. Standard concentrations of Wortmannin (100 nM) and 
LY294002 (10 µM) were used as control treatments. Given the fact that the chemical stability 
of AS041164 under these conditions was unknown, 24 hours after starting the test the same 
amount of all inhibitors and vehicle was added to the probes for 48 h treatment. To avoid 
maximum cell density before the measurement, the initial number of cells in samples for 48 h 
treatment was reduced by 50%. The cells were counted with Beckman-Coulter Z2 particle 
counter and the cell samples were stained with propidium-iodide (PI) and fluorescein 
diacetate (FDA) prior to flow cytometry analysis. We made an assumption that the ratio of 
metabolically active cells (FDA positive) could not significantly differ from the percentage of 
viable cells under this conditions. Indeed, there was less then 1% of the cells that were double 
negative or double positive for PI and FDA staining.  
Results in Figure 2.6. show that 24 h treatment of Jurkat cells with 10 µM AS041164 
insignificantly reduces the cell number and has practically no impact on the cell viability. 30 
µM AS041164 after 24 h showed slightly stronger reduction of the cell number but the 
margins of error were still close to those of mock-treated cells. 48 h treatment with both 
concentrations of AS041164 showed insignificant difference to the mock-treated cells. The 
relatively small cytotoxicity of Wortmannin, especially after 24 h treatment, can be explained 
by its documented chemical instability. Presented data confirmed preliminary results obtained 
with Neubauer counting chamber and tripan-blue exclusion (data not shown). The results 
pointed to the two conclusions: that AS041164 showed very low, practically insignificant 
cytotoxicity under described conditions, and also that AS041164 was differing from 
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Wortmannin and LY294002 under given conditions regarding the impact on the proliferation 
and viability of Jurkat cells. 
A       
B  
Figure 2.6. The number and viability of Jurkat cells after 24 h (A) and 48 h (B) of 
treatment with different PI3K inhibitors ; used concentrations are indicated. 24 h after the 
commencement of the test, the same amount of all inhibitors and vehicle was added to the 
probes for 48 h treatment as the chemical stability of AS041164 under this conditions was 
unknown. Cells were counted by Beckman-Coulter Z2 particle counter, and the analysis was 
performed by flow cytometry; PI positive cells were accounted as dead and FDA positive 
cells were considered as viable. 
 
In order to elucidate the inhibitory potential and selectivity of AS041164, several 
simple inhibitory analyses were performed. The major aim of this experiment was to compare 
possible inhibitory effects of AS041164 with the effects of wortmannin and LY294002 in 
Jurkat cells. We made an assumption that the level of activation/phosphorylation of Akt/PKB 
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could be considered as a reflection of intracellular PtdIns(3,4,5)P3 level, or indirectly as a 
reflection of overall PI3K activity. Jurkat cells are exceptional in this regard because they do 
not express (or at least do not express functional) PTEN and SHIP, and their basal level of 
PtdIns(3,4,5)P3 is constantly high, but can be further enhanced by various kinds of stimuli. 
We therefore examined the efficiency of wortmannin- and LY294002-induced inhibition of 
Akt/PKB phosphorylation in Jurkat cells under different conditions. 
 
Figure 2.7. Inhibition of Akt/PKB activation in Jurkat cells by wortmannin and 
LY294002. Serum deprived and Jurkat cells maintained in standard conditions were 
incubated with indicated concentration of PI3K inhibitors for 30 minutes. The cells were 
lysed, and protein lysat was resolved on 10% SDS-PAGE followed by immuno-blotting with 
antibody specific for activated Akt/PKB. Western blot for Akt/PKB obtained from the same 
membrane after the stripping represents loading control. 
 
Standard concentrations, two-fold and five-fold higher concentration of both inhibitors 
were applied to the serum-deprived cells and to the cells in the standard conditions. Both 
substances show clear, dose-dependent and rapid inhibition of PI3Ks in Jurkat cells. This 
effect is significantly enhanced and/or accelerated by serum-deprivation (Figure 2.7.). 
 The next step was to compare the effect of AS041164 and wortmannin in a short 
time-course treatment with serum-deprivation and in the standard conditions (Figure 2.8.). 
AS041164 was apparently a weak inhibitor of Akt/PKB activation and it seemed to have a 
small impact on overall PI3K kinase activity, especially in the standard conditions.  
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Figure 2.8. Inhibition of Akt/PKB activation in Jurkat cells by wortmannin and 
AS041164. Serum deprived and Jurkat cells maintained in the standard conditions were 
incubated with the indicated concentration of inhibitors during a time-course. The cells were 
lysed at indicated time points, and protein lysat was resolved on 10% SDS-PAGE followed by 
immunoblotting with antibody specific for activated Akt/PKB. Western blot for Akt/PKB 
obtained from the same membrane after the stripping represents loading control. 
 
 
Figure 2.9. Inhibition of Akt/PKB activation in Jurkat cells by LY294002 and 
AS041164 during 24 hors time-course. Jurkat cells maintained in the standard conditions 
were incubated with indicated concentration of inhibitors during a 24 h time-course. The cell 
samples were lysed at indicated time points, the protein lysat was resolved on 10% SDS-
PAGE followed by immuno-blotting with antibody specific for activated Akt/PKB. Western 
blots for Akt/PKB and b-actin, obtained from the same membrane after the stripping, 
represent loading controls. 
 
The inhibitory effect of AS041164 on Akt/PKB activation was also compared to the 
effect of LY294002 during a 24 h time-course treatment of Jurkat cells in the standard 
conditions (Figure 2.9.). These results again showed that PI3Kg specific inhibitor was 
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differing from LY294002 and that it had minor effect on overall PI3K enzymatic activity 
under given conditions. 
It was proved that activation of G-protein coupled receptors (GPCR) by 
lisophosphatidic acid (LPA) also induces activation of PI3Kg and bifurcation of its lipid- and 
protein-kinase activity which leads to activation of Akt/PKB and MAPK, respectively 
(Bondeva et al., 1998). Thus, we decided to test the ability of AS041164 to inhibit Akt/PKB 
and Erk 1/2 activation with and without LPA stimulation in Jurkat cells. As shown in Figure 
2.10., AS041164 is a week inhibitor of Akt/PKB activation in comparison to wortmannin, 
both before and after LPA stimulation. On the other side, AS041164 appears to be a relatively 
good inhibitor of LPA-induced activation of Erk under the same conditions. 
 
Figure 2.10. Inhibition of Akt/PKB and Erk activation in Jurkat cells by 
wortmannin and AS041164 +/- LPA stimulation. Serum-deprived cells were treated with 
indicated concentrations of inhibitors 30 minutes prior to stimulation, stimulated with 
indicated concentrations of LPA for 10 minutes and lysed. Protein lysat was resolved on 10% 
SDS-PAGE. Immuno-blotting was done with specific antibodies for activated Akt/PKB and 
activated Erk 1/2. Western blots against Erk 1/2 obtained from the same membrane after the 
stripping represent loading control. 
 
 Our results confirmed that wortmannin and LY294002 perform strong, rapid and dose-
dependent inhibition of PI3Ks in Jurkat cells, which was enhanced by serum deprivation. On 
the other side, AS041164, unlike wortmannin and LY294002, performed a week inhibition of 
Akt/PKB activation in serum-deprived Jurkat cells. The same substance had undetectable 
influence on overall PI3K enzymatic activity of Jurkat cells kept in the standard conditions 
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and no significant cytotoxicity within the applied range of concentrations. This data, along 
with the information provided by the manufacturer, confirmed that AS041164 could be 
considered and used as PI3Kg specific inhibitor in our model system. 
 
2.4. PI3Kg  specific inhibitor AS041164 reduces IL-2 production upon anti-CD3-
iducet activation of Jurkat cells 
The next aim was to examine whether the application of AS041164 on anti-CD3-
activated Jurkat cells can reduce IL-2 production and in this way reproduce some of the 
features of PI3Kg-/- T cells. Mouse monoclonal antibody against human CD3 complex (clone 
OKT3) coupled to the solid surface via goat anti-mouse IgG (GAMI) was used for the cell 
activation. Treatment with Ionomycin (IONO) and phorbol ester (TPA) was used as a positive 
control for the activation, and the treatment of activated cells with 10 µM LY294002 was 
taken as a confirmative control of PI3Ks inhibition. The cells were kept in the standard 
conditions during the whole experiment. The inhibitors were applied 15-20 minutes prior to 
the activation, and the treatment took 24 hours. IL-2 concentration in cell culture supernatant 
was measured by ELISA. As shown in Figure 2.11., AS041164 reduced IL-2 production of 
activated Jurkat cells in a concentration dependent manner, unlike 10 µM LY294002, which 
completely blocked anti-CD3-induced IL-2 production. We could not exclude the possibility 
that the activated Jurkat cells were more susceptible to a possible cytotoxic effect of 
AS041164, so reduced IL-2 production may have been caused by a reduced number and/or 
viability of the activated cells. The additional viability tests with PI and FDA staining were 
therefore performed with the same samples (Figure 2.12.).  
Our results showed that AS041164 reduced IL-2 production in anti-CD3-activated 
Jurkat cells in a dose-dependent manner. The reduction could not be justified by reduced cell 
viability as a consequence of treatment with the inhibitor. Diminished cell activation or 
disrupted signalling downstream from TCR caused by AS041164 treatment is more likely to 
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be the reason for this reduction. Moreover, the kinase activity and not only the presence of 
PI3Kg appeared to be important for TCR-induced IL-2 production in Jurkat cells. 
 
 Figure 2.11. IL-2 production upon activation of Jurkat cells. Cells were activated 
by mouse monoclonal anti-CD3 antibody (clone OKT3) immobilised to the solid surface via 
goat anti-mouse IgG (GAMI) or by IONO/TPA as positive control. Cells were treated with 
indicated concentrations of inhibitors. Samples were taken 24 h after the activation, and IL-2 
concentration in the cell culture supernatant was measured by ELISA. 
 
 
 Figure 2.12. Cell number and the viability of Jurkat cells 24 h after the activation. 
Analysis performed by flow cytometry after PI and FDA staining. 
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2.5. The impact of PI3Kg  specific inhibitor AS041164 on some signalling pathways 
related to the activation of TCR in Jurkat cells 
Presented data along with previously known facts, clearly implicated that PI3Kg is 
involved in activation-induced IL-2 production in T cells. We therefore investigated the 
possible impact of AS041164 on some of TCR-induced signalling pathways in Jurkat cells. 
TCR-induced activation of PI3Ks is well documented, but the mechanism of this activation is 
not completely elucidated, and several proposed models are exclusively related to PI3K class 
IA enzymes (reviewed by Okkenhaug and Vanhaesebroeck, 2003b). Wortmannin and 
LY294002 generally inhibit activation of primary T cell but they are considered to be 
relatively ineffective in Jurkat cells (reviewed by Kane and Weiss, 2003). These discrepancies 
regarding the inhibitory impact of those two substances on Jurkat cells activation are mostly 
related to CD28 co-stimulation (Crooks at al., 1995). However, in our experiments we did not 
use any type of costimulation parallel with CD3 stimulation. Our earlier results proved that 
wortmannin and LY294002 perform rather strong and consistent PI3K inhibition under the 
conditions we used for the following experiments (serum deprived Jurkat cells, the inhibitor 
was applied 30 minutes prior to the stimulation). Mouse monoclonal antibody against TCR, 
clone C305 (an antibody which reacted with idiotypic-like determinants expressed on Jurkat 
cells; Weiss et al., 1984) was used for the activation. Soluble C305 antibody binds and 
activates TCR of Jurkat cells and induces signalling processes downstream and in the 
proximity of TCR, but it does not cross-link the receptors and does not induce full-scale 
activation of the cells. Nonetheless, it is a useful and commonly used tool for investigation of 
the initial steps of TCR-induced T cell activation. 
Activation of several relevant signalling proteins was investigated in parallel: 
Akt/PKB activation as one of the major target of PI3K enzymatic activity, and activation of 
three parallel MAPK pathways (represented by Erk 1/2, p38 and SAPK/JNK) upon TCR-
induced activation. 
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A  
B  
C  
D  
Figure 2.13. The effect of 10 µM AS41164 on A) Akt/PKB activation, B) Erk 1/2 
activation, C) SAPK/JNK activation and D) p38 activation upon TCR stimulation of 
Jurkat cells with C-305 monoclonal antibody. The stimulation was stopped at indicated 
time-points, cells were lysed and total cell lysat was resolved on 10% SDS-PAGE followed 
by immunoblotting with specific antibodies. Second western blots are obtained from the same 
membranes after the stripping and represent corresponding loading controls.  
 
Results presented in Figure 2.13. were obtained with 10 µM AS041164. This 
concentration was approximately at the middle of recommended range. In all our experiments 
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where this concentration induced clear alterations of read-outs we could not detect any 
unspecific inhibition. 10 µM AS041164 reduced Akt/PKB activation in serum-deprived none-
stimulated Jurkat cells (Figure 2.13.A), but did not have any detectable impact on Akt/PKB 
activation upon TCR activation. Moreover, there was not any detectable impact of the same 
substance on Erk 1/2 (Figure 2.13.B) and SAPK/JNK (Figure 2.13.C) phosphorylation. 
Interestingly, the treatment of Jurkat cells with 10 µM AS041164 slightly enhanced p38 
activation, both in none-stimulated cells and at least at the beginning of the TCR-stimulation 
(Figure 2.13.D). The significance of this result remains unclear. The pattern of tyrosine 
phosphorylation of proteins typical for TCR activation was examined as well (data not 
shown). Again, there were no detectable changes after the treatment of activated Jurkat cells 
with the inhibitor.  
In conclusion, AS041164 did not exhibit any significant changes in the activation of 
Akt/PKB and MAPK in activated Jurkat cells, implicating that PI3Kg may not be directly 
involved in the regulation of these pathways upon T cell activation, or at least, PI3Kg may not 
be involved in the initial, acute phase of TCR-induced activation of Jurkat cells. 
 
2.6. PI3Kg interacts with different PKC isoforms in Jurkat cells 
Our next goal was to try to identify interacting partners of PI3Kg in Jurkat cells, 
especially the proteins whose interaction with PI3Kg appears to be regulated by TCR 
signalling. Jurkat cells were stimulated with anti-TCR mouse monoclonal antibody C305 for 
10 minutes. Anti-PI3Kg immunoprecipitation was performed, the samples with corresponding 
controls were resolved on SDS-PAGE and the gels were silver-stained (Figure 2.14.). 
Particular bands, which seemed specific and altered by the stimulation were isolated, digested 
by tripsin and the peptide fragment samples were analysed and identified by mass-
spectrometry (MS). The most important finding of those analyses was identification of several 
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isoforms of protein kinase C (PKC). The results were confirmed by several independent 
immunoblotting experiments.  
We confirmed that a PI3Kg ?in Jurkat cell constitutively interacts with four isoforms of 
PKC. The amount of those coprecipitated proteins, and possibly the strength of interaction 
declines in a range PKCa>PKCb1>PKCb2>PKCz. The signal coming from coprecipitated 
PKCz was much weaker then signals from other isoforms, slightly above the level of 
background and it should be therefore carefully evaluated. Any similar interactions between 
PI3Kg ?and PKCe, PKCd, PKCq  and PKCh isoforms were not detectable. This was an 
additional proof that registered signals were not artefacts coming from unspecific binding of 
PKCs to PI3Kg, to the antibody or to the G-protein sepharose beads. 
 
Figure 2.14. Non-stimulated Jurkat cells or cells stimulated with anti-TCR antibody 
C305 for 10 minutes were lysed and the anti-PI3Kg immunoprecipitation was performed with 
specific mouse monoclonal antibody, clone 641. The samples and corresponding controls 
were resolved on 10% SDS-PAGE and the gel was stained with silver. Bends representing 
potential specific interacting partners of PI3Kg were extracted from the gel and analysed by 
MS. The arrows point to some of the analysed samples. The samples identified as PKC and 
PI3Kg (as positive control) are indicated. The image presents one of four such gels from 
independent experiments.  
 
We tried to elucidate the nature of this interaction by performing an inhibitory 
analysis. Four different inhibitors have been used: LY294002 as strong, unspecific inhibitor 
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of all PI3Ks, AS041164 as specific PI3Kg inhibitor and Bisindolylmaleimide I and Gö 6976 
as two different, but well documented inhibitors of PKCs (Figure 2.15). Non-stimulated 
Jurkat cells were treated with the inhibitors and anti-PI3Kg immunoprecipitation was 
performed. Immunoblotting was made with antibodies specific for eight aforementioned PKC 
isoforms .  
LY294002 almost completely abolished interaction between PI3Kg and four 
interacting PKC isoforms indicating that these interactions were highly correlated with 
Akt/PKB (and probably PDK1) activation and seemed likely to be PtdIns(3,4,5)P3-dependent. 
AS041164 also reduced these interactions but to a lesser extent in comparison to LY294002 
(Figure 2.15.). That was an indication that these interactions may not be fully dependent on 
kinase activity of PI3Kg; it seemed more likely that PI3Kg kinase activity enhanced these 
already existing, constitutive interactions in Jurkat cells. Surprisingly, the inhibition of all 
four PKC isoforms by both PKC inhibitors enhanced the amount of coprecipitated PKC 
isoforms, meaning that PKC inhibition actually increased the interactions between PI3Kg and 
PKCs.  
The attempts to coprecipitate any PKC isoforms by PI3Kg immunoprecipitation from 
resting human CD4 T cells isolated from peripheral blood gave no results (data not shown). It 
was already mentioned that Jurkat cells have extremely high level of PtdIns(3,4,5)P3 due to 
the fact that PTEN and SHIP in these cells are mutated and dysfunctional. Hence, the results 
obtained from human CD4 T cells support an assumption that those interactions are indeed 
PtdIns(3,4,5)P3-dependent. Consistent with this is the fact that anti-CD3 activation of Jurkat 
cells further elevated the level of PtdIns(3,4,5)P3 and enhanced the Akt/PKB activation, but 
also increased the interaction of PI3Kg and PKCb1 and PKCb1 (Figure 2.15.D).  
  2. Results 
 46
A    B   
C    D   
Figure 2.15. A) Co-immunoprecipitation of PKCa . B) Co-immunoprecipitation of 
PKCb 1 and PKCb 2. Jurkat cells were kept in standard conditions, treated with indicated 
concentrations of inhibitors for 30 minutes, lysed and anti-PI3Kg immunoprecipitation was 
performed. C) The impact of the same inhibitors on phosphorylation of Akt/PKB. D) Co-
immunoprecipitation of PKCb 1 and PKCb 2 after the stimulation of Jurkat cells TCR. 
Cells were serum-deprived, stimulated with C305 antibody for 10 minutes, lysed and a-PI3Kg 
immunoprecipitation was performed. Corresponding loading controls were obtained with the 
same membranes after the stripping.  
 
On the western blot images presented in Figure 2.15A and -B, it can be visualised that 
the signals for PKCs coming from the total cell lysat were much stronger then the signals 
coming from the immunoprecipitation samples. The amount of the total cell lysat loaded on 
the gel was roughly 10% of the lysat used for the immunoprecipitation. Concerning the fact 
that PKCa, PKCb1 and PKCb2 are abundant cytosolik molecules, this may suggests several 
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explanations which do not necessarily exclude each other: first, a relatively small portion of 
total PKCs interacts with PI3Kg under given conditions; second, these interactions may be 
rapid and transient; third, the interactions may be mediated via one or more other molecules; 
and fourth, stechiometry of this interaction may be in favour of PI3Kg. 
The newly discovered interaction between two signalling proteins, especially between 
two kinases, always brings the question if this is an enzyme-substrate interaction. Several 
attempts with different conditions and stimulations, followed by immunoprecipitations and in 
vitro protein-kinase assays, did not confirm this assumption - no transphosphorylation 
between PI3Kg and any of PKC isoforms was detected (data not shown). It should be taken 
into consideration that similar interactions have been registered in a different model, where 
certain results implicated that PI3Kg can be the substrate for of PKCs (personal 
communication to Prof. Matthias Wymann, University of Basel, unpublished data).  
Taken all together, PI3Kg is in constitutive interactions with several PKC isoforms 
(PKCa, PKCb1, PKCb2 and probably PKCz) in Jurkat cells. These interactions seem to be 
PtdIns(3,4,5)P3-dependent and their constitutive nature is apparently specific for Jurkat cells. 
Described protein-protein interactions were enhanced by TCR activation, and surprisingly, by 
PKC inhibition. Moreover, these interactions were facilitated by the kinase activity of PI3Kg, 
but without evidence that interactions between PI3Kg and PKC isoforms were kinase-
substrate interactions. 
 
2.7. PKC inhibitor and PI3Kg  specific inhibitor reduce TCR activation-induced IL-2 
production of Jurkat  cell in a similar manner 
The activation of T cells with Ionomycin (IONO) and phorbol-ester (TPA) is 
commonly used in vitro as a positive control for lymphocytes activation and cytokine 
production. Treatment with Ionomycin and TPA completely by-passes all cell-surface 
receptors including TCR, boosts intracellular calcium influx and activates the members of 
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protein kinase C family beside other signalling proteins, respectively. It is known that TCR 
mediated Ca2+ flux of PI3Kg-/- T lymphocytes is comparable with the WT T cells, ergo 
observed differences in T cell activation and cytokine production cannot be explained by 
differences in Ca2+ flux (Sasaki et al., 2000). We therefore examined if there may be any 
correlation in inhibition of PI3Kg and PKCs related to the reduced IL-2 production.  
The additional samples in our cell activation and IL-2 production assay were included: 
IONO/TPA activation inhibited with 30 µM AS041164 and 1 µM Bisindolylmaleimide I, and 
also, anti-CD3 activation inhibited with three different concentrations of Bisindolylmaleimide 
I and AS041164 (Figure 2.16.). It is known that the PKCs inhibitors diminish both TCR-
induced and IONO/TPA-induced activation and cytokine production. Although 1 µM 
Bisindolylmaleimide I represents relative excess of the inhibitor, the aim for using this 
concentration was to obtain full PKC inhibition and clear-cut differences. The cells were 
activated with immobilised OKT3 antibody as described for the previous experiments. 
 
 Figure 2.16. The inhibition of PI3Kg  and PKCs reduces the IL-2 production of 
activated Jurkat cells. The cells were treated with indicated concentrations of inhibitors 
during 24 hours of activation in standard conditions. The IL-2 concentration in the cell 
supernatant was measured by ELISA. 
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1 µM Bisindolylmaleimide I blocked IONO/TPA-induced IL-2 production while 30 
µM AS041164 reduced it for about 30%. Interestingly, the reduction of anti-CD3-induced  
IL-2 production in a concentration-dependent manner showed similar pattern for both 
(AS041164 and Bisindolylmaleimide I) inhibitors. In this experiment, as well as in all other 
performed experiments, AS041164 showed a consistently stronger inhibition of CD3-induced 
IL-2 production than IONO/TPA-induced IL-2 production. On the other side, 
Bisindolylmaleimide I showed the opposite trend in the inhibition efficiency regarding the 
two different types of the cell activation.  
 
2.8. PI3Kg  regulates IL-2 expression of activated Jurkat cells on different levels 
The results presented above indicated that PI3Kg involvement in the control of IL-2 
expression upon the activation of Jurkat cells was related to the role of different PKC 
isoforms, and this involvement probably might take place on different levels, e.g. 
transcriptional, post-translational or secretion levels. We therefore decided to perform 
additional experiments and IL-2 assay in order to focus on the two different but closely 
related issues: the expression of early activation markers on the cell surface as one of first 
results of altered transcription, and the level of IL-2 transcription and secretion as one of the 
ultimate outcomes of T cell activation. First of all, extra samples were included and new IL-2 
assay was performed after 24 hour treatment (see Figure 2.17.). The cells from the samples 
were used for the analysis of the activation by flow cytometry. 
CD69 is a type II integral membrane protein and it is a phosphorylated, disulfide 
linked 27/33 kDa homodimer composed of differentially glycosylated subunits with an 
extracellular C-type lectin domain. The CD69 is considered as a very early marker of 
lymphocyte activation and it is commonly used as a parameter of T cell activation. We 
measured the percentage of activated Jurkat cells as ratio of viable (PI negative) and CD69+ 
cells, 24 h after the stimulation (Figure 2.17.). 1 µM Bisindolylmaleimide diminished 
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IONO/TPA-induced activation of Jurkat cell. This is to be expected if one of the major targets 
of activation and the only target of inhibition are PKCs. The inhibitory effect of 10 µM 
LY294002 was much weaker in this case, while 10 µM and 30 µM AS041164 did not show 
any reduction of CD69+ cells. The CD3-induced CD69 expression was reduced to a similar 
extent both by 1 µM Bisindolylmaleimide and 10 µM LY294002, while 10µM AS041164 
again did not show any influence on CD69 expression. Considering that all observed effects 
of AS041164 were clearly dose-dependent and highly reproducible, it is very unlikely that 
3µM AS041164 would have any influence on the percentage of CD69+ cells in these 
experiments. On the other side, in experiments with CD3-iduced activation 30 µM AS041164 
performed inhibition comparable to the effects of Bisindolylmaleimide I and LY294002, 
raising the question about the selectivity of the inhibitor at this particular concentration under  
given conditions (Figure 2.17.).  
 
 Figure 2.17. Percentage of viable CD69+ Jurkat cells 24 hours after the activation 
with IONO/TPA or CD3-induced activation. Only viable cells (PI negative) were taken 
into account.  
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 Measurements of IL-2 production from the same experiments (Figure 2.18.) proved 
again that the inhibition of PI3Kg kinase activity reduces IL-2 production both in Jurkat cells 
activated with IONO/TPA and those activated via TCR. This inhibition was always 
concentration-dependent and stronger in TCR-activated samples. AS041164-induced 
inhibition of IL-2 production was considerably weaker than inhibition caused by 10 µM 
LY294002, although both PI3Kg specific inhibitor and LY294002 act in a similar way and 
both substances were applied within the same range of concentration. Again, if there were any 
doubts about the selectivity of 30 µM AS041164, the effects of 3 µM and 10 µM AS041164 
on IL-2 production were clear and highly reproducible, while the selectivity of these lower 
concentrations of the inhibitor appeared to be beyond any doubts. 
 
Figure 2.18. The inhibition of PI3Kg  reduced IL-2 production of activated Jurkat 
cells. The cells were activated with IONO/TPA or with anti-CD3 (OKT3) antibody and 
treated with indicated concentrations of inhibitors during the 24 hours of activation in 
standard conditions. IL-2 concentration in the cell supernatant was measured by ELISA. 
 
Additional experiments with the same pattern of activation and inhibition were performed in 
order to correlate the amount of secreted IL-2 and its transcription (Figure 2.19.). RNA was 
isolated at the same time point as for the other analyses, 24 hours upon activation. This time 
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point was taken as a compromise in order to obtain comprehensive analysis of all read-outs 
obtained from this type of experiments. 
 
Figure 2.19. The inhibition of IL-2 transcription in activated Jurkat cells by 
different concentrations of AS041164. Jurkat cells were activated with IONO/TPA or with 
anti-CD3 (OKT3) antibody and treated with indicated concentrations of inhibitors during the 
24 hours of activation in the standard conditions. The intensity of RT-PCR signal for IL-2 was 
normalised according to the intensity of the signals for b-actin obtained from the identical 
samples. The values are recalculated as the percentage of the positive probe for the given type 
of activation. The results represent one of the five independent experiments. 
 
Both Bisindolylmaleimide I and LY294002 were strong inhibitors of IL-2 
transcription in IONO/TPA-activated Jurkat cells, while different concentrations of 
AS041164 exhibited drastic differences in their performance: treatment with 3 µM AS041164 
slightly increased IL-2 transcription, most probably due to the delayed peak of activation. 10 
µM AS041164 showed week repression and 30 µM AS041164 inhibited this transcription to 
the approximately same extent as Bisindolylmaleimide I and LY294002. TCR(CD3)-induced 
IL-2 transcription was much weaker and its suppression by different inhibitors was slightly 
different: while Bisindolylmaleimide I and LY294002 reduced the IL-2 transcription to less 
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than half, AS041164 inhibited the transcription in a concentration-dependent manner – from 
moderate to strong inhibition like non-selective PKC and PI3K inhibitors. 
Our results showed that specific inhibitor of PI3Kg effected the expression of CD69 in 
Jurkat cells activated via TCR only when it was applied as 30 µM, the concentration with 
questionable selectivity under described conditions. In all other cases of activation/inhibition 
AS041164 had no effect on CD69 expression. This implicates that PI3Kg was dispensable for 
certain aspects of cell activation and subsequent transcriptional regulation. On the other side, 
inhibition of the PI3Kg effected IL-2 production in a concentration-dependent manner both in 
the cells activated with IONO/TPA and in the cells activated via TCR, in which case 
AS041164 exhibited a considerably stronger inhibitory effect. At the same time, the reduction 
of IL-2 transcription induced by the treatment with different concentrations of AS041164, 
could not fully justify the reduction in secreted IL-2. Discrepancies between experimental 
results from IL-2 RT-PCR, level of CD69 expression and measurements of secreted IL-2 
indicate once more that used inhibitors, and especially AS041164, might have impact on IL-2 
expression in activated Jurkat cells on different levels, from transcription to secretion. 
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3. Discussion 
 
3.1. PI3Ks and T cell activation 
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases involved in regulation 
of diverse biological functions, including cell growth, differentiation, survival, proliferation, 
migration and metabolism. PI3Ks are indispensable for the differentiation and functions of the 
T cells. This family of enzymes is a key component of the TCR signalling pathway. The 
major product of their lipid-kinase activity, phosphatidyinositol 3,4,5-triphosphate 
(PtdIns(3,4,5)P3), is an important second messenger that regulates the activity of numerous 
TCR-related proteins, such as PDK1, Akt/PKB, Vav-1, Itk, PLCg1, Ras and many others. To 
our knowledge, in previously published works, the TCR-induced activation of PI3Ks was 
almost exclusively related to the class IA PI3K (a, b  and d isoforms). Several models of this 
PI3K activation were proposed, but none of them was so far fully accepted. All of them 
include few important prerequisites for the full activation of PI3K: translocation of PI3K to 
the plasmamembrane, indirect association with ITAMs on the cytoplasmatic tail of TCR via 
regulatory subunits and involvement of protein tyrosine kinases and/or different 
transmembrane adaptor proteins. PI3K activation occurs within seconds of TCR activation, 
and PI3Ks remain active for nine hours or more (Costello et al., 2002). The first clear 
evidences of PI3Kg involvement in the T cell activation-induced proliferation and cytokine 
production came with the generation of PI3Kg KO mice (Sasaki et al., 2000). In our study we 
tried to elucidate the nature of PI3Kg involvement  in T cell functions and the mechanism 
behind this. 
 
3.2. The features of PI3Kg -/- T cells 
PI3Kg KO mice show reduced number of thymocytes and mature T cells, and the 
functions of p110g-/- T cells are impaired. All previous results clearly indicate that PI3Kg is 
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not indispensable for T cell homeostasis and function, but rather an important modulator of 
development, activation and activation-induced cytokine production in T cells. Our data 
showed reduction of the number of thymocytes and mature T cells in peripheral lymphoid 
organs and partly confirm earlier findings (Sasaki et al., 2000; Rodriguez-Bolardo et al., 
2003). We described that disruption of p110g had an even stronger impact on the mouse 
phenotype, especially regarding the number of T cells in spleen and lymph nodes, effecting 
both major subpopulations of mature T cells (CD4+ and CD8+ cells). There could be a few 
reasons for this discrepancy. First, slightly different gene-targeting strategies were applied on 
the mouse strain with a different genetical background. Sasaki et al. (2000) used C57BL/6 
(commonly known as ‘Black 6’) mice while the mice we used for our study belonged to 
129/sv inbred line (provided by the group of E. Hirsch). Second, the animals we used were in 
average several weeks older, many of them being close or at the beginning of their sexual 
maturity.  
Our results concerning the reduced number and altered ratio of major thymocytes 
subpopulations also clearly indicated severely impaired thymic growth and cellularity, as well 
as disrupted T cell development and differentiation. Rodriguez-Bolardo et al. (2003) 
described this effect in more details by proving that PI3Kg is involved in thymocyte 
development on at least two levels. First, PI3Kg-/- thymocytes have impaired DN-to-DP 
transition at pre-TCR stage (designated as DN stage III) and diminished proliferative 
expansion that accompanies this stage. Furthermore, PI3Kg-/- thymocytes exhibit altered 
CD4/CD8 lineage commitment during positive selection. Nonetheless, it seems more likely 
that such seriously disrupted thymic growth and development should also have serious 
consequences on the number of peripheral mature T cells, instead of having minor effects as 
described by Sasaki et al. (2000). In contrast to the reduced number, the ratio of different 
subpopulations of resting mature PI3Kg-/- T cells (who passed the bottle-neck in their thymic 
development), including  the ratio of CD4+ and CD8+, was comparable with the ratio of WT.  
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However, our results about proliferation of mouse PI3Kg-/- T lymphocytes confirmed 
an earlier observation from Sasaki et al. (2000). PI3Kg-/- T cells do have reduced proliferation 
in response to activation by an anti-CD3 antibody and CD28 costimulation was able to rescue 
this impaired proliferation. We found out that the impaired proliferation of the same T cells 
could also be rescued by IL-2 costimulation. Given the fact that reduced cytokine production 
of TCR-activated PI3Kg-/- T cells cannot be rescued by CD28 co-stimulation, as well as with  
Ionomycin- and phorbol ester-induced activation, this clearly indicated that the lack of IL-2 
expression (and probably some other cytokines as INFg) may be the major reason for this 
malfunction. The same fact may explain impaired functions of PI3Kg-/- T cells in vivo (Sasaki 
et al., 2000), where costimulation (like CD28 activation) of T cells is present by default 
during TCR-induced activation. 
 
3.3. Jurkat cells are good model to investigate the function of PI3Kg  in the T cells 
For already more than twenty years Jurkat cells have been the most commonly used 
model for investigating human T lymphocytes. The majority of the facts known nowadays 
about TCR structure, its function and related signalling pathways, have emerged from studies 
performed with this cell line (Abraham and Weiss, 2004). The core aspects of these processes 
that have been defined in Jurkat cells are relevant in physiological settings. Nevertheless, 
Jurkat cells, like any other model, show some limitations and disadvantages. Shan et al. 
(2000) proved that this particular cell line does not express a detectable level of PTEN, while 
other authors (Astoul et al., 2001) proved the same for SHIP. The absence of these two 
phosphatases in Jurkat cells results in an abnormally high level of PtdIns(3,4,5)P3 and slower 
termination of PI3K signalling pathways upon treatment with PI3K inhibitors. According to 
Astoul et al. (2001) Jurkat cells have a five-fold higher basal level of the PtdIns(3,4,5)P3 than 
basal level of PtdIns(4,5)P2, and further, a two-fold increase of PtdIns(3,4,5)P3 level can be 
detected upon TCR activation. The same authors used A20 cells for comparison, and in 
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contrast to Jurkat cells, A20 cells had a very low basal level of PtdIns(3,4,5)P3, lower than the 
basal level of PtdIns(4,5)P2. Triggering the B cell receptor of A20 cells induced a 10- to 12-
fold increase in the PtdIns(3,4,5)P3 level. Consequences of the abnormalities in Jurkat cells 
are constitutive membrane localisation of Itk (Shan et al., 2000,) and Akt/PKB, enhanced 
activity of PDK1 (Baier, 2003), as well as constantly high phosphorylation of glycogen 
synthase kinase 3 (GSK3), an endogenous substrate for activated Akt/PKB, and abnormal 
GTPase-controlled actin regulation (Astoul et al., 2001) (Figure. 3.1.).  
 
Figure 3.1. Specific features of Jurkat cells. Like in all other cells lines the 
activation of PI3K class I is connected to the protein tyrosine kinases (PTK), while PI3Kg is 
activated via G-protein coupeled receptors (GPCR). Two lipid phosphatases PTEN and SHIP, 
the negative regulators of the PtdIns(3,4,5)P3 level, are absent in Jurkat cells. Contribution of 
the PI3Kg to the overall PI3Ks lipid-kinase activity in Jurkat cells is relatively small. The 
basal level of PtdIns(3,4,5)P3 is constantly high resulting in the recruitment of the proteins 
containing PH domains (e.g. Itk, PDK1, Akt/PKB) to the plasmamebrane. In addition, this 
translocation enhances the activity of PDK1, which in return activates Akt/PKB and PKCs. 
Activated Akt/PKB phosphorylates and blocks GSK3, BAD and caspase-9, and in this way 
induces a strong anti-apoptotic signal.  
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Does all this make Jurkat cells an inappropriate model for investigating the role of 
PI3K in T cells? In vivo T cells follow a chemokine gradient that recruits them into the 
relevant secondary lymphoid organ where they can encounter the antigen presenting cells. 
This migration requires activation of both chemokine and integrin signalling pathways which 
are both linked to the activation of PI3Ks. Moreover, memory T cells respond to the cytokine 
interleukin 15 (IL-15), which also activates PI3Ks. Hence, in vivo TCR triggering will 
normally occur in the cells that have activated PI3Ks already. Jurkat cells are therefore a good 
model to study TCR signalling in chemokine-activated normal cells or IL15-stimulated 
memory cells, as long as the data obtained from these cells are interpreted bearing in mind 
that PI3K signalling is abnormal (Astoul at al., 2001). 
Our results indicated that the contribution of PI3Kg to the overall PI3Ks lipid-kinase 
activity in Jurkat cells is relatively small, practically insignificant in standard conditions when 
the huge excess of PtdIns(3,4,5)P3 is constantly present within the cell. Nevertheless, the 
inhibition of PI3Kg in activated Jurkat cells induced a specific, clear-cut effect, rather similar 
to the effect of gene disruption in KO mice. It was therefore justified to use Jurkat cells in our 
experiments as a model to investigate the role of p110g by using the specific inhibitor 
AS041164. 
 
3.4. AS041164 is a selective inhibitor of PI3Kg  in Jurkat cells 
It is well known that both Wortmannin and LY294002 are cytotoxic for primary cells. 
However, Jurkat cells appear to tolerate relatively low concentrations of both substances 
because of their abnormally high level of PtdIns(3,4,5)P3. In our experiments 100 nM 
Wortmannin, and especially 10 µM LY294002, significantly reduced the rate of cell 
proliferation and viability of the Jurkat cells. On the other side, 10µM and 30 µM AS041164 
did not have any significant impact on cell viability and cell-cycle progression of Jurkat cells 
in the standard conditions. Different kinds of lymphocyte activation in vitro always induce 
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apoptosis, meaning that the number and viability of the proliferating cells are reduced to a 
different extent. Activation with Ionomycin and TPA dramatically reduced viability of the 
activated Jurkat cells in contrast to the CD3-induced activation. 10µM and 30 µM AS041164 
did not reduce the viability of Jurkat cells activated in both ways. Moreover, the inhibitor 
appeared to rescue the activated cells from apoptosis, unlike 10 µM LY294002, which 
reduced both total cell number and the percentage of activated Jurkat cells. This was another 
proof that the inhibitor kept desirable selectivity in our experimental setting. Hence, any 
outcome of the AS041164 application on Jurkat cells in the low micro-molar range could not 
be caused by the cytotoxic effect of this inhibitor. 
Akt/PKB is one of the major targets of PI3Ks lipid-kinase activity. Actually, Akt/PKB 
binds PtdIns(3,4,5)P3 and PtdIns(4,5)P2 via its PH domain, and translocates to the 
plasmamembrane where PDK1 phosphorylates threonin 308 in the kinase activating loop of 
Akt/PKB (Komander et al., 2004). Further phosphorylation of serine 473 in the C-terminal 
regulatory domain is associated with full activation of AKT/PKB and it is performed by one 
still unknown kinase designated as PDK2 (Seminario and Wange, 2003). PDK1 is also 
recruited to the plasmamembrane after interaction of its PH domain with PtdIns(3,4,5)P3 and 
PtdIns(4,5)P2. Binding of PDK1 to these lipids does not appear to change the intrinsic kinase 
activity of the enzyme; it seems that this interaction enhances PDK1 kinase activity by 
bringing the enzyme and its substrates in close contact. There are few data that indicate how 
PDK1 activity is regulated, but PDK1 is considered to be constitutively active (Seminario & 
Wange, 2003). The constitutively high level of PtdIns(3,4,5)P3 in Jurkat cells enhances kinase 
activity of PDK1 and the activation of Akt/PKB. Indeed, the Jurkat cells we used exhibited 
relatively high level of Akt/PKB activation even after some hours of serum-deprivation. The 
level of full Akt/PKB activation, that is Akt/PKB phosphorylation on serine 473, can 
therefore be considered as a read-out of the intracellular PtdIns(3,4,5)P3 level and reflection of 
overall PI3K activity.  
  3. Discussion 
 60
In order to clear-out aforementioned controversies about the efficiency of the PI3K 
inhibition by Wortmannin and LY294002 in Jurkat cells (reviewed by Kane and Weiss, 2003, 
and Seminario and Wange, 2003) we performed a set of simple inhibitory analyses. We 
observed that inhibition of the Akt/PKB phosphorylation by Wortmannin and LY294002 was 
faster and/or more efficient in serum-deprived Jurkat cells than in the cells maintained in the 
standard conditions, but in both cases the inhibition was clear and concentration-dependent. 
For that reason, in order to avoid any possible side-effects caused by large surplus of the 
inhibitors, for further experiments we decided to use the lowest concentrations of these 
inhibitors applied in our initial tests.  
The next step was to compare possible influence of the AS041164 on Akt/PKB 
phosporylation in Jurkat cells with the impact of wortmannin and LY294002. Our data 
showed that 10 µM AS041164 was a week inhibitor of  Akt/PKB phosphorylation in serum-
deprived Jurkat cells and it did not show a detectable inhibitory effect in Jurkat cells 
maintained in the standard conditions, both during the short-term (1 h) and long-term (24 h) 
treatment. Again, AS041164 exhibited significant differences to general PI3K inhibitors. If 
we postulate that AS041164 displays acceptable selectivity under the described conditions, 
we can also assume that the contribution of the PI3Kg to the overall PI3K lipid-kinase activity 
in Jurkat cells (without any specific stimuli and under the standard conditions) is relatively 
small.  
LPA stimulation of Jurkat cells induced PI3Kg-dependent activation of both Akt/PKB 
and Erk 1/2. This activation was Wortmannin sensitive, that is PI3K-dependent, and the only 
PI3K isoform clearly proved to be activated by GPCR agonists is PI3Kg (Lopez-Ilasaca et al., 
1997). 100 nM Wortmanin practically blocked Akt/PKB activation, both in serum-deprived 
non-activated cells and in LPA-stimulated Jurkat cells. The reduction of Erk 1/2 activation by 
100 nM Wortmanin under the same condition appeared to be less effective, especially with 
the higher concentration of the LPA. On the other side, 10 µM AS041164 exhibited different 
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pattern of the inhibition: it was a week inhibitor of Akt/PKB activation, and a potent inhibitor 
of LPA-induced Erk 1/2 activation. One would expect that under given conditions both 
inhibitors should perform nearly the same pattern of the inhibition, but these inhibitors are 
apparently two substances with different features and different modes of action.  
Direct involvement of PI3Kg in the signalling pathways connected to the TCR and 
related tyrosine kinases was never proved, but our results, along with earlier findings, clearly 
indicated that inhibition PI3Kg kinase activity disrupted at least some of the signalling events 
and/or processes initiated by the TCR activation. We therefore decided to examine the impact 
of the PI3Kg specific inhibitor on the activation of Akt/PKB and MAPK upon TCR 
activation. The investigated pathways are known to be activated by TCR in a PI3K-dependent 
manner, and they are linked to the activation of transcription factors responsible for TCR-
induced IL-2 production. Serum deprived Jurkat cells were activated by a soluble clonotypic 
C305 antibody which induces a strong, rapid and transient activation of Akt/PKB, Erk 1/2, 
p38 and SAPK/JNK, as well as typical pattern of tyrosine phosphorylation of many proteins 
involved in TCR signalling. Possible effects of the inhibition were monitored during a 60 
minutes time-course. Above mentioned results, with exception of the p38 activation, did not 
show any changes in activated Jurkat cells pre-treated with the PI3Kg specific inhibitor. 
Surprisingly, the phosphorylation of p38 was slightly enhanced, but we were not able to 
elucidate the significance of this observation. Taken all together, these results indicated that, 
whatever the nature of PI3Kg involvement in the TCR-induced activation of the Jurkat cells 
may be, it does not seem to be in the proximity to the TCR in signal transduction and it does 
not seem to regulate the initial steps of this process. Nevertheless, no matter how insignificant 
may look the reduction of Akt/PKB activation in serum-deprived non-stimulated samples, it 
should not be overlooked. Retained expression of PTEN in Jurkat cells had minor effects on 
early PI3K-dependent TCR signalling events, in contrast to distal signalling events, including 
IL-2 production, CD69 up-regulation and activation of NFAT/AP-1, which were all inhibited 
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by PTEN expression (Seminario et al., 2003). PTEN ineffectively opposed the acute changes 
in PtdIns(3,4,5)P3 level induced by TCR activation, but the phosphatase clearly 
downregulated the basal level of inositide. 
 
3.5. Selective inhibitor of PI3Kg reduces IL-2 production in activated Jurkat cells 
The PI3Kg specific inhibitor AS041164 was a weak inhibitor of Akt/PKB activation in 
serum-deprived Jurkat cells and showed practically no impact on Akt/PKB activation in the 
cells maintained in standard conditions, as well as in activated Jurkat cells. AS041164 seemed 
to influence neither level of PtdIns(3,4,5)P3 nor the activation of PDK1, and it certainly did 
not reduce Akt/PKB activation under standard conditions. In contrast, AS041164-induced 
reduction of IL-2 production in activated Jurkat cells was clear, dose-dependent and highly 
reproducible. These results, along with the data obtained from PI3Kg KO mice, point to the 
conclusion that cytokine production of activated p110g-/- T cells was most probably not 
impaired due to the absence of p110g or a lack of its lipid-kinase activity, because the excess 
of PtdIns(3,4,5)P3 is constantly present in Jurkat cells. It seems more likely that this effect 
was caused by the lack of p110g protein-kinase activity itself or by other properties of the 
enzyme (e.g. subcellular localisation or certain protein-protein interactions) which depend on 
the protein-kinase activity.  
 
3.6. p110g  interact with different PKC isoforms in Jurkat cells 
Our results proved that PI3Kg interacts with four different PKC isoforms in Jurkat 
cells. For more than a decade the protein members of the PKC family have been known to 
play a key role in the T cell activation (Barry and Nishizuka, 1990; Dreikhausen et al., 2003). 
It is well known that pleiotropic PKC inhibitors block T cell activation (Wilkinson et al., 
1998), but T lymphocytes contain up to eight different species of PKC isoforms, making it 
difficult to determine the specific cellular function of these individual enzymes (Baier, 2003). 
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Moreover, the PKC signalling system appears to be highly versatile, cell-type- and 
differentiation status-dependent. Regulation of PKC expression and activity operate at the 
transcriptional, translational and post-translational levels, including the active mechanisms for 
PKC degradation (Baier, 2003). It is therefore not surprising that the reports on involvement 
of particular PKC isoforms in the processes like T cell activation and IL-2 production often 
gave conflicting results.  
PKCa was considered to be the major PKC isoform involved in TCR/CD28 signalling 
pathways and responsible for the generation of the transcription factors AP-1 and NFAT 
(Genot et al., 1995; Dreikhausen et al., 2003). Dreikhausen et al. (2003) proved overlapping 
biological activities of PKCa and PKCb  in activation of the MAPK pathway and NF-kB, but 
claimed that PKCb1 is the major regulator of TCR-CD28-induced IL-2 gene transcription and 
secretion in Jurkat cells. Another model and another approach led to a rather different result: 
Long et al. (2001) proved that PKCb  is specifically involved in the secretion but not in the 
transcription of IL-2 in activated HUT 78 cells. Many studies in different T cell lines also 
indicated that PKCq, a lymphocyte specific PKC isoform, plays a significant role in T cell 
activation (Ghaffari-Tabrizi et al., 1999; Kempiak et al., 1999; Altman et al., 2000), which 
was confirmed with the generation of PKCq KO mice (Pfeifhofer et al., 2003). Peripheral T 
cells lacking PKCq failed to activate NF-kB and AP-1, and failed to express IL-2 upon TCR-
induced activation. However, stimulation of these cells with Ionomycin and phorbol ester 
restored IL-2 transcription and proliferation. Trushin et al. (2003) proved that both PKCa and 
PKCq are required for the activation of T cells and subsequent expression of IL-2R and IL-2 
production. Their results clearly placed PKCa upstream from PKCq in these signalling 
events, implicating that PKCa is responsible for the activation of transcription factors NF-kB 
and NF-AT, but not AP1, upon CD3/CD28-induced activation. The same authors used both 
Jurkat cells and human peripheral blood T cells in their study, combining genetic analysis, 
pharmacological inhibitors and RNA interference.  
  3. Discussion 
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Interaction of p110g with PKCa, PKCb1, PKCb2 and PKCz in Jurkat cells is 
constitutive and LY294002 sensitive. Treatment of the cells with this PI3Ks inhibitor 
drastically diminished those interactions, which highly correlated with a reduced level of 
PtdIns(3,4,5)P3 and a reduction of Akt/PKB activation. The enzyme members of the protein 
kinase C family are multi-domain proteins with a complex multi-level regulation of their 
activation. The following pattern of activation refers to the group of conventional PKCs (a, 
bI, bII and g isoforms), but other PKC isoforms are activated in a similar manner. First, PKCs 
are allosterically regulated by their N-terminal pseudosubstrate – the release of the 
pseudosubstrate from the kinase core is an initial step of the activation. Besides, binding of 
diacylglycerol (in vivo) or phorbol ester (in vitro) to the C1 domain of PKCs strongly 
increases affinity of the enzyme for membranes. Binding of Ca2+ ions to the C2 domain also 
facilitates recruitment of PKCs to the membrane. The functions of both C1 and C2 domains 
appear to be synergistic, but independent. Three stages of phosphorylation are required for the 
full activation of PKCs. The initial and rate-limiting step in this process is phosphorylation of 
the target threonin residue in activation loop by PDK1. This is followed by phosphorylation 
of the threonin residue in turn motif, which locks PKC in a catalytically competent, thermally 
stable, and phosphatases resistant conformation (Edwards et al., 1997; Newton, 2001). 
Finally, phosphorylation of (predominantly) a serine residue in the C-terminal hydrophobic 
motif affects the sub-cellular localisation and stability of PKCs. It is known that all PKC 
isoform subclasses can form complexes with PDK1 and that PKC phosphorylation in the 
activation loop by PDK1 is blocked by LY294002 (reviewed by Parekh et al., 2000). Taking 
in consideration abnormally high levels of PtdIns(3,4,5)P3, and therefore the same abnormally 
high PDK1 kinase activity in Jurkat cells (Baier, 2003), as well as the proved pattern of PKC 
activation, it can be assumed that the level of PKC kinase activity in Jurkat cells must also be 
elevated, but still be Wortmannin and LY294002 sensitive. 
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On the other side, inhibition by AS041164 reduced the interaction between p110g and 
PKC isoforms which implicates that p110g kinase-activity might not be essential, but 
important to enhance the interactions of p110g and PKC isoforms in Jurkat cells. Very 
surprisingly, two PKC inhibitors (Bisindolylmaleimide I and Gö 6976) also enhanced the 
interactions between p110g and PKC isoforms. This may be explained by results of Hu and 
Exton (2004) who investigated interaction between PKCa and Phospholipase D1. They came 
to some unexpected results: first, inhibition of PKCa by Bisindolylmaleimide I and Ro-31-
8220 induced phosphorylation of threonin residue(s) of the enzyme in vivo, and then, the 
same inhibitors induced translocation of PKCa to the plasmamembrane. Bisindolylmaleimide 
I and Gö 6976 also blocked PMA-induced translocation of PKCa to the perinuclear region, 
but not PMA-induced translocation of PKCa to the plasmamembrane. This suggests the 
conclusion that predominantly or only active and not inhibited p110g and translocated PKC 
isoforms interact in the vicinity of the plasmamembrane. This could explain why it was not 
possible to detect these interactions in non-stimulated human peripheral blood CD4+ T cells, 
and why those interactions are enhanced in Jurkat cells upon TCR stimulation. The answer 
could be that interactions between p110g and activated PKC isoforms in primary human T 
lymphocytes take place only after the antigen receptor activation, and that this interaction is 
probably rapid and transient. 
  
 3.7. The interaction of 110g  and PKC isoforms is important for IL-2 production of 
activated Jurkat T cells 
The specific p110g inhibitor AS041164 and PKCs inhibitor Bisindolylmaleimide I 
reduced anti CD3-induced production of IL-2 in a similar, dose-dependent way. When IL-2 
production was induced by Ionomycin and phorbol-ester bypassing TCR and directly 
activating PKCs among other targets, the impact of AS041164 on IL-2 production was much 
weaker, unlike the effect of Bisindolylmaleimid I, which completely blocked IL-2 production. 
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This implicates that p110g kinase-activity is required for the proper functioning of the 
aforementioned PKC isoforms upon TCR activation in order to induce cytokine production. 
One possibility is that all this enzymes are part of a larger signalling complex, and it is likely 
that p110g facilitates the recruitment of PKCa, -b1, and -b2 (and –z) to the plasmamembrane, 
into the vicinity of PDK1, the major physiological activator of PKCs (Figure 3.2.). Ionomycin 
and TPA activation of Jurkat cells can obviously overcome the problem of PKCs 
translocation to the plasmamembrane when PI3Kg is inhibited. This may be the reason why 
AS041164 is less effective inhibitor of IL-2 production when the cells are activated in this 
way. Bearing in mind that PDK1 activation is also dependent on the PtdIns(3,4,5)P3 level, this 
may explain why p110g-PKCs interactions are more sensitive to Wortmannin and LY294002 
than to AS041164.  
The involvement of PI3Kg in IL-2 expression upon Jurkat cell activation may be 
located on several levels from the regulation of transcription to the export of IL-2 from the 
cells. It is known that the induction of transcription from one of the IL-2 promoter’s sites by 
NFAT requires both calcium- and PKC/Ras-dependent pathways (Rao et al., 1997; Kane and 
Weiss, 2003). PI3Kg-/- cells produce reduced amounts of IL-2 and interferon-g (INF-g) in 
response to treatment with anti-CD3e and anti-CD28e or ConA. This functional defect was 
also present in PI3Kg-/- cells activated with IONO/TPA, a stimulus that bypasses the initial 
TCR-activation signalling events. Moreover, TCR-mediated Ca2+ flux, tyrosine 
phosphorylation, and activation of tyrosine kinases were comparable among PI3Kg+/- and 
PI3Kg-/- T cells (Sasaki et al., 2000). It therefore seems that the cause of reduced IL-2 
production of activated PI3Kg-/- T cells on the transcriptional level may be disruption of a 
PKC/Ras-dependent but not a calcium-dependent pathway. 
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 Figure 3.2. The interaction of PI3Kg  with PKCa , -b 1, -b 2 and –z in activated T 
cells. Antigen binding to the TCR induces signalling cascade that activates PI3Ks class IA, 
while the direct influence of TCR activation on the PI3Kg remains elusive. The activated 
enzymes rapidly increase the level of PtdIns(3,4,5)P3 which enhances the kinase activity of 
PDK1 among other enzymes. Activated PLCg1 creates DAG which binds to the C1 domain of 
PKCs, and Ins(1,4,5)P3 which induces Ca2+ influx. Calcium ions bind to the C2 domain of 
PKCs and together with DAG induce translocation of PKCs to the plasmamebrane. In vitro 
activation with Ionomycin and TPA makes the same effect on PKCs, like some PKC 
inhibitors which also facilitate the translocation of PKCs. PI3Kg facilitates the recruitment of 
PKC isoforms in the vicinity of the plasmamembrane, where PKCs become phosphorylated 
by PDK1. Proper activation of different PKCs is necessary for the IL-2 expression. 
  
The expression of IL-2 is regulated in very complex way, which is quiet common for 
many cytokines. The complexity of regulation enables tight control of cytokine production 
and release. Antigen recognition by the TCR and activation of the T lymphocytes induces 
specific transcription factors. Several studies demonstrated a requirement for cooperative 
binding of the three transcription factors, AP-1, NF-AT, and NF-kB for maximal IL-2 
production (Chen and Rothenberg, 1994; Garrity et al., 1994; Novak et al., 1990). NFAT 
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binds to the promotor region of the IL-2 gene and activates its transcription. Induction of 
transcription does not lead by default to the production of IL-2: in primary T cells CD28 
costimulation is required for the stabilisation of IL-2 mRNA. Cytokine promotors have 
constant, low basal activity, but their mRNAs are short-lived because of the ‘instability’ of 
their 3’ untranslated region. Stabilisation of the IL-2 mRNA increases IL-2 synthesis by 20- 
to 30-fold. Activation of transcriptional factors AP-1 and NF-kB leads to a further 3-fold 
increase in IL2 production, so these two effects together increase IL-2 production by as much 
as 100-fold (Janeway et al., 2001). The peak of IL-2 transcription in Jurkat cells activated by 
phorbol ester and ionophore can be registered 6-7 hours after the stimulation, while TCR-
induced IL-2 transcription reaches its peak several hours later (Weiss et al., 1987; Wiskocil et 
al., 1985). 
RT-PCR results for IL-2 clearly showed that AS041164 inhibited IL-2 transcription in 
a dose-dependent manner. Ionomycin/phorbol ester-induced IL-2 transcription was strongly 
inhibited both by Bisindolylmaleimide I and LY294002 confirming the importance of both 
PKCs and PI3Ks in this process. Two different kinds of cell activation gave a slightly 
different pattern for the inhibition by AS041164. In ionomycin/phorbol ester-activated cells 
treatment with the lowest concentration of AS041164 sligtly increased transcription of IL-2, 
whereas higher concentrations of the inhibitor reduced IL-2 transcription in a dose-dependent 
manner. In contrast secretion of IL-2 was downregulated with all concentrations of the 
inhibitor. A sligtly different picture emerged upon CD3-activation of Jurkat cells. In this case 
secretion and transcription of IL-2 were reduced by all concentrations of the PI3Kg-specific 
inhibitor AS041164 in a dose-dependent manner. This shows that PI3Kg may be involved in 
the control of IL-2 production on several levels from transcription to secretion, and that at 
least one of these levels is connected to PKCs. Although the level of reduction may be 
slightly different the significant differences on the various regulatory levels point to the 
conclusion that various modes of protein activity of PI3Kg allow distinct interactions with 
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different signalling pathways, suggesting that PI3Kg is a multifunctional enzyme important 
for the regulation of lymphocytes at different cellular levels. 
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4. Materials and Methods 
 
 4.1. Materials 
4.1.1. Cells 
Jurkat cells were purchased from German Collection of Microorganisms and Cell 
Culture (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig), 
DSMZ No ACC 282, LOT 7.   
 
 Antibodies 
4.1.2. Primary antibodies used for western blotting 
Mouse monoclonal anti-b-actin antibody, clone AC-15, Sigma 
Rabbit polyclonal antibody to Human PKC a (C-20), (cs-209), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC bI (C-16), (cs-209), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC bII, (cs-210), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC q (C-18), (cs-212), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC d (C-17), (cs-213), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC e (C-15), (cs-214), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC z (C-20), (cs-216), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Human PKC h (C-15), (cs-215), Santa Crus Biotechnology 
Rabbit polyclonal antibody to Phospho-SAPK/JNK (Thr183/Tyr185), #9251, Cell Signaling 
Technology, NEB 
Rabbit polyclonal antibody to SAPK/JNK, #9252, Cell Signaling Technology, NEB 
Rabbit polyclonal antibody to Phospho-p38 MAP Kinase (Thr180/Tyr182), #9211, Cell 
Signaling Technology, NEB 
Mouse monoclonal antibody to Phospho-p42/44 MAPK (P-Erk 1/2) (Thr202/Tyr204), #9106, 
Cell Signaling Technology, NEB 
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Mouse monoclonal antibody to p42/44 MAPK (Erk 1/2) (L34F12), #4696, Cell Signaling 
Technology, NEB 
Rabbit polyclonal antibody to Phospho-Akt (P-Akt) (Ser473), #9271, Cell Signaling 
Technology, NEB 
Rabbit polyclonal antibody to Akt, #9272, Cell Signaling Technology, NEB 
 
4.1.3. Secondary antibodies used for western blotting 
Goat anti-mouse IgG (H+L), Peroxidase-Labeled (KPL, Gaithersburg, MD, USA) 
Goat anti-rabbit IgG (H+L), Peroxidase-Labeled (KPL, Gaithersburg, MD, USA) 
 
 4.1.4. Antibody used for immunoprecipitation 
Anti-PI3Kg mouse monoclonal antibody, clone 641, hybridoma culture supernatant 
(hybridoma cells are the property of ‘AG Molekulare Zellbiologie, Klinikum der FSU Jena’) 
Mouse IgG2A isotype control (Sigma) 
 
4.1.5. Antibodies and conjugates used for purification of mouse T cells 
 FITC-anti-B220 (Caltag, Burlingame, CA, USA) 
FITC-anti-CD11b (Caltag, Burlingame, CA, USA) 
FITC-anti DX5 (BD Pharmingen) 
BioMag® Sheep anti-fluorescein particles (Polysciences Inc., Warrington, PA, USA) 
 
4.1.6. Antibodies used for activation of mouse T lymphocytes and Jurkat cells 
Hamster monoclonal Anti-Mouse CD3e antibody, clone 145-2C11, cat. Nr. 553057 (BD 
Pharmingen) 
Goat Anti-Mouse IgG + IgM (H+L) (GAMI) (Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) 
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Mouse Monoclonal Anti-Human CD3, clone OKT3 (eBioscience, San Diego, CA, USA) 
C305 mouse monoclonal antibody which reacted with idiotypic-like determinants expressed 
on Jurkat cells (Weiss et al., 1984), hybridoma culture supernatant (a kind gift from Professor 
B. Schraven, Institute of Immunology, University of Magdeburg) 
 
4.1.7. Antibodies used for the flow cytometry analysis 
FITC-Conjugated Mouse Anti-Human CD69 Monoclonal antibody, clone FN50, Catalogue 
Number: 555530 (BD Pharmingen) 
FITC-Conjugated Anti-Mouse CD3 Molecular Complex Monoclonal Antibody, clone 17A2, 
Catalogue Number: 555274 (BD Pharmingen) 
R-Phycoeritrin (R-PE) conjugated anti-mouse CD4 (L3T4) monoclonal antibody, clone 
H129.19, Catalogue Number: 553652 (BD Pharmingen) 
PER-CP-conjugated anti-mouse CD8 monoclonal antibody, clone 53-6.7, Catalogue Number: 
553036 (BD Pharmingen) 
FITC-conjugated anti-mouse TCR b-chain monoclonal antibody, clone H57-597, Catalogue 
Number: 553171 (BD Pharmingen) 
 
4.1.8. Buffers 
Dulbeccos Phosphate Buffer Saline, D-PBS (Gibco) 
FACS buffer (D-PBS, 1% BSA; Gibco) 
Lysis buffer for immunoblotting (20 mM HEPES, 10 mM EGTA, 40 mM b-
glycerophosphate, 2,5 mM MgCl2, 1% NP-40 alternative, 10 mM NaF, 2 mM Na3VO4, 100 
µM PMSF and 1 µg/ml Aprotinin) 
5x gel loading buffer, GLB (10% SDS, 25% glycerol, 25% b-mercaptoethanol) 
Anode buffer for semi-dry transfer (0,3 M Tris, 20% methanol, pH 10,4) 
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Cathode buffer for semi-dry transfer (25 mM Tris, 20% methanol, 40 mM 6 amino-n-caproic 
acid, pH 9,4) 
Tris buffer saline/Tween 20 - TBST (50 mM Tris, 150 mM NaCl, 2,7 mM KCl, 0,1% Tween 
20, pH 7,5) 
Lysis buffer for immunoprecipitation (100 mM TRIS/HCl pH 7.5, 150 mM NaCl, 1 mM 
MgCl2 and 0.25% NP-40 substitution) 
Wash buffer for immunoprecipitation (100 mM TRIS/HCl pH 7.5, 100 mM NaCl, 1mM 
MgCl2 and 0.05% Tween-20) 
 
 4.1.9. Primers (MWG-Biotech, Germany) 
IL-2 sense: AACCTCAACTCCTGCCACAATG 
IL-2 anti-sense:  CAAGTTAGTGTTGAGATGATGC 
b-actin sense: TACATGGCTGGGGTGTTGAA 
b-actin anti-sense: AAGAGAGGCATCCTCACCCT 
 
4.1.10. Other reagents and chemicals 
 (dT)18 primer (MWG-Biotech, Germany) 
[methyl-3H]thymidine (Amersham) 
10 mM dNTP’s (MWG-Biotech, Germany) 
3MM Whatman filter papers (Biometra, Göttingen, Germany) 
AMV Reverse Transcriptase (Promega) 
AS04116 (Serono Company, Geneva) 
Biomax® film (Kodak) 
Bisindolylmaleimide I (Calbiochem) 
Biomag Sheep anti-fluorescein particles (Polysciences Inc.), 
Bradford Reagent (Sigma) 
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BSA, cell culture tested (Sigma) 
Cell culture flasks (Grainer) 
Cell strainers, pore size 70 µm (BD Falcon) 
DNase I, RNase free (Roche) 
Enhanced Chemiluminescence reagent - ECL (Western Lightning®; Pierce) 
Ethidium bromide (Sigma) 
Fluorescein diacetate (FDA; ICN Biomedicals) 
Foetal calf serum (Gibco) 
Glass Fibre Filters, Filtermat A (Wallac Oy, Turku, Finland) 
Gö 6976 (Calbiochem) 
G-protein Sepharose beads (GammaBind®; Amersham) 
Imobilion-P Transfer Membrane (PVDF; Millipore) 
Ionomycin, Free Acid, from Streptomyces conglobatus (Calbiochem) 
LPA (L-a-lysophospatidic acid, Oleoyl, Sodium; Sigma) 
LY-294002 (Alexis Biochemicals) 
Non fett milk powder (Roth, Karlsruhe, Germany)  
p(dN6) random primer (Roche) 
Penicillin/streptomycin for the cell culture(Gibco)  
PMA (TPA or Phorbol 12-myristate 13-acetate; Alexxis Biochemicals) 
Ponceau S (AppliChem, Germany) 
Propidium iodide (PI; Sigma)  
Quantykine Human IL2 ELISA (R&D System, Minneapolis, USA) 
Recombinant Human Interleukin 2 (IL-2; BD Pharmingen) 
Rneasy Mini Kit (Qiagen) 
RPMI 1640 medium with GlutaMax® (Gibco)  
Sequencing grade methylated trypsin (Sigma) 
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Tag Polymerase (Qiagen) 
Tripan Blue (Sigma) 
U-bottomed 96-well plate (Costar) 
Wortmannin (Alexis Biochemicals)  
b-mercaptoethanol, 2-mercaptoethanol (Sigma) 
 
4.2. Methods  
4.2.1. Cell cultivation 
Jurkat cells were maintained in the standard conditions for the activation of the cells 
with immobilised OKT3 antibody, both before and during the assay, as well as for the 
inhibitory analysis where indicated. Cells were maintained at 370C with 5% CO2 in 250 ml 
plastic cell culture flasks, RPMI 1640 medium with supplemented with 10% foetal calf 
serum. The medium was exchanged every 2-3 days, depending on the cell density, before they 
reached density of 1.5x106/ml.  
Serum deprivation of Jurkat cells was performed over night (approximately 16 hours) 
in RPMI 1640 medium supplemented with 0,25% of cell culture tested BSA, incubation at 
370C with 5% CO2.  
Mouse T lymphocytes purified from the spleen and used for the functional assays were 
maintained under standard conditions: incubation at 370C with 5% CO2 in plastic cell culture 
flasks, RPMI 1640 medium supplemented with 10% foetal calf serum, 100U/ml penicillin, 
100 µg/ml streptomycin and 3,5 µl/l of b-mercapto-ethanol. 
 
4.2.2. Isolation of the mouse lymphocytes 
The experimental animals were sacrificed with pressurised CO2. The whole intact 
lymphoid organs (thymus, spleen, lymph nodes) were extracted under aseptic conditions and 
transferred into the petri dishes with ice-could PBS, washed and the blood and residues of  the 
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surrounding tissue were removed (Figure 2.1.). The organs were transferred into separate cell 
strainers with pore size of 70 µm. Each cell strainer was submersed in the petri dish filled 
with 10 ml ice-could medium. The organs were homogenised inside of the cell strainer by 
using 1 ml syringe plunger with rubber top. Cell suspension was collected from the petri dish, 
transferred to the 15 ml polypropylene conical centrifuge tubes and centrifuged for 10 
minutes at 1200 rpm, 40C. The cell pellet was resuspended in 10 ml of ice-could medium and 
the washing step was repeated three times in total. The cells were counted with Neubauer 
counting chamber using tripan-blue exclusion.  
 
4.2.3. Purification of the mouse T cells 
Mouse T lymphocytes used for the functional assays were purified from spleen by 
negative selection. Isolated lymphocytes samples were resuspended in 200 µl PBS/1% BSA. 
Following antibodies ware added in the cell suspension: 10 µl of FITC-anti-B220, 10 µl of 
FITC-anti-CD11b and 5 µl of FITC-anti DX5. The cells were incubated with the antibodies 
for 30 minutes at 40C and afterwards washed three times with 1 ml of PBS/1% BSA. After the 
final washing step cell pellet was resuspended in 500 µl of PBS/1% BSA. 1,5 ml anti-FITC 
magnetic beads suspension (Biomag Sheep anti-fluorescein particles), washed three times 
with 500 µl of PBS/1% BSA, were retained with the magnet, resuspended in 500 µl of PBS 
with 1% BSA and mixed with 500 µl of the cell suspension. The mixture was gently rotated 
for 30 minutes at 40C. The beads were separated with a magnet twice, each time retaining the 
supernatant with T cells. Purified T cells were resuspended in the medium and prepared for 
the further use. The cell purity was confirmed by flow cytometry analysis (FACScalibur, BD) 
after the staining with FITC-anti-CD3 antibody. The obtained yield was 91 - 94%.  
  4. Materials and Methods 
 77
 
 
 
Figure 4.1. Mouse lymphoid organs. The whole intact thymus and spleen were 
extracted for the analyses; caudal, inguinal, brachial, axillary, deep and superficial cervical 
lymph nodes were extracted and used for the analysis of the T cells in lymph nodes. T cells 
purified from the spleen were used for functional assays. 
 
4.2.4. Staining of the mouse T cells with specific antibodies for the flow cytometry 
analysis 
For each sample, 1 x 106 cells were stained with antibodies and analysed on a 
FACSCalibur® using the CellQuest® software (Becton Dickinson). All the antibodies were 
purchased from BD Biosciences and the cell staining was performed according to the 
manufacturer’s recommendation. Briefly: the 100-fold dilution of antibody mixture was 
prepared in cold FACS buffer. The samples were distributed in U-bottomed 96-well plate, the 
plate was centrifuged (1000 rpm, 40C) and the cell pellet was resuspended in 100 µl of 
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antibody mix solution. After the incubation at 40C for 30 minutes, the cells were washed three 
times with FACS buffer, transferred to the FACS tubes and resuspended in final volume of 
500 µl FACS buffer.   
 
4.2.5. Activation of the mouse T cells and proliferation assay ([3H]-thymidine 
uptake) 
Purified mouse T cells (2.5 x 104 cells/well) were cultured under standard conditions 
in a U-bottomed 96-well plate in the presence of plate-bound anti-mouse CD3 antibody  
(Simeoni et al., 2005b). The plate was pre-incubated for 2 h at 370C with 100 µl per well of 
the indicated antibody concentrations. The cells were transferred in the plate, cultured for 72 h 
and labelled with 0.5 µCi/well of [3H]thymidine during the last 6 h. The incubation was 
terminated by filtration through Glass Fibre Filters by using TOMTEC Mach III cell harvester 
(Orange, CT, USA), and the filter was dried and frozen at –200C. The read-out was obtained 
24 hour later on Wallac 1450 (Wizard automatic Microbeta counter, Wallac Oy, Turku, 
Finland). 
 
4.2.6. Flow cytometry analysis of the Jurkat cells viability (PI and FDA staining) 
and Jurkat cell activation (CD69 staining) 
For viability test 2,5x105 Jurkat cells per sample were stained with fluorescein 
diacetate (FDA) in concentration of 0.04 µg per 100 µl of cell suspension and propidium 
iodide (PI) in concentration of 25 µg per 100 µl of cell suspension in FACS buffer (Ross et 
al., 1989). Samples were incubated for 15 min at room temperature in dark, washed and 
resuspended in FACS buffer.  
For the analysis of the activation 2,5x105 Jurkat cells per sample were stained with 
FITC-conjugated mouse anti-human CD69 monoclonal antibody. The staining was performed 
according to the manufacturer’s protocol: the cells were suspended in 100 µl of FACS buffer, 
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incubated with 5 µl of antibody for 30 min in dark at 40C. The cells were washed and 
resuspended in FACS buffer. 
Stained Jurkat cells were analysed using a FACS®Calibur (Becton Dickinson) and 
CellQuest Pro (BD) analysis software. Excitation and emission settings were 488 nm and 
525–550 nm (FL1 filter) for FDA and FITC-anti-CD69 and 488 nm and 564–606 nm (FL2 
filter) for PI staining, respectively. 
 
4.2.7. Immunoblotting  
The samples of the Jurkat cells were washed with ice-could PBS, resuspended by 
vortexing in 100 µl per 1 million cells of ice-could lysis buffer and left on ice for 10 minutes. 
The samples were centrifuged for 20 minutes at 15000 rpm, 40C, and the supernatant 
containing proteins was transferred into the new 1,5 ml micro test tubes. The protein 
concentration was measured with Bradford reagent (Sigma) according to the manufacturer’s 
protocol (absorbance at 595 nm). Total cell protein lysate was kept at –200C until further use. 
The aliquots of the lysate containing 25-50 µg of proteins were mixed with appropriate 
volume of the 5xGLB, boiled for 5 minutes at 950C and resolved on 10% SDS-PAGE 
(Sambrook and Russell, 2001). The resolved proteins were transferred on the PVDF 
membrane using semi-dry system according to the manufacturer’s protocol with slight 
modifications. Briefly, in semi-dry blotting device the gel and the membrane were 
sandwiched between three sheets of 3MM Whatman filter papers soaked with anode and 
cathode buffer. Constant current of 2.5 mA/cm2 was applied for one hour. The efficiency of 
the transfer was controlled with Ponceau S staining of the membrane. The membranes were 
blocked either in 5% non fat milk or 5% BSA dissolved in TBST for one hour at room 
temperature. The detection of the proteins was performed by using respective mouse 
monoclonal or rabbit polyclonal antibodies diluted according to the manufacturers’ 
recommendation, followed by incubation with appropriate secondary antibody conjugated to 
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the HRP. Both after the incubation with primary and the secondary antibody the membranes 
were washed five times for five minutes in TBST buffer. The proteins were visualised by 
applying ECL solution on the membrane for one minute, the membrane was wrapped in a 
transparent foil and finally, Biomax® film (Kodak) was exposed to the membrane. 
 
4.2.8. The stimulation of Jurkat cells with C305 antibody 
The samples of Jurkat cells in serum-free medium were aliquoted in 1,5 ml micro test 
tubes (106 cells in 400 µl per tube) and kept during stimulation in the Thermomixer at 370C, 
1000 rpm. 100 µl of hybridoma culture supernatant containing C305 mouse monoclonal 
antibody (a kind gift from Professor B. Schraven, Institute of Immunology, University of 
Magdeburg) was added to the samples, and the activation was terminated at indicated time-
points by adding 1 ml of ice-could PBS. The cells were centrifuged for 2 minutes at 40C, 1000 
rpm. The cell pellet was washed with 1 ml of ice-could PBS and resuspended in 100 µl of 
lysis buffer for immunoblotting. 
 
4.2.9. Anti-CD3-induced activation of Jurkat cells 
24-well plates were incubated with 250 µl per well of 2 µg/ml Goat-anti-mouse IgG 
(GAMI) for 2 h at 370C. Plates were washed with D-PBS and afterwards incubated with 250 
µl per well of 2 µg/ml anti-CD3 monoclonal antibody OKT3 for 2 h at 370C. Plates were 
washed with D-PBS. Jurkat cells were collected, counted, centrifuged and resuspended in 
standard medium at cell density of 106 cells/ml. The aliquots of the cell suspension were 
treated for 15 minutes prior to the activation with following amounts of inhibitors where 
indicated: 10 µM LY294002, 3, 10 or 30 µM AS041164 (as indicated in the text), 1 µM 
Bisinolylmaleimide I. 500 µl aliquot from each cell suspension was distributed to one well. 
Each treatment was made in triplicate. Treatment with 1 µg/ml of Ionomycin, (IONO) and 10 
µM Phorbol 12-myristate 13-acetate (PMA or TPA) was used as a positive control. Negative 
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controls were mock-treated cells and cells treated only with GAMI (2 µg/ml). Homogeneous 
cell suspension from each sample was collected 24 h later, samples were centrifuged at 1000 
rpm for 2 minutes, and 100 ml of supernatant was used for IL-2 measurement. Remaining cell 
pellet was used for RNA extraction.  
 
4.2.10. Measurement of IL-2 production in activated Jurkat cells 
Concentration of IL-2 in supernatant was determined with Quantykine Human IL2 
ELISA according to the manufacturer’s instructions. Briefly, a monoclonal antibody specific 
for IL-2 has been pre-coated onto a microplate. 100 µl of prepared standards and samples 
were pipetted into the wells along with 100 µl of assay buffer and any IL-2 present was bound 
by the immobilized antibody during 2 hours of incubation at RT. After three washing steps, 
an HRP-coupled polyclonal antibody specific for IL-2 was added to the wells for another 2 
hours of incubation. Following three more washing steps, a substrate solution was added to 
the wells. The colour development was stopped with stop-solution and the intensity of the 
colour was measured with TECAN Ultra plate reader (Tecan Group, Mannedorf/Zurich, 
Switzerland), readout at 450 nm wave length, and referent absorbance at 620 nm. 
 
4.2.11. Immunoprecipitation of PI3Kg   from Jurkat cells 
107 Jurkat cells were lysed in 500µl of lysis buffer for immunoprecipitation. The 
lysate from each sample was incubated with 100 µl of culture supernatant from 641 
hybridoma (mouse monoclonal anti-PI3Kg antibody, Lot 121204) for 2 h at 40C with rotation. 
G-protein Sepharose beads (GammaBind®) were aliquoted into separate micro test tubes, 15 
µl of slurry that approximately corresponds to 10 µl of the solid beads, washed and 
equilibrated with lysis buffer, and the total cell lysate was transferred into the micro test tubes 
with the Sepharose beads. Samples were incubated for another 2 h at 40C with rotation. The 
beads were washed three times with wash buffer, and 100 µl of 1xGLB was added to each 
sample. Samples were boiled at 950C for 5 minutes and resolved in 10% SDS-PAGE. 
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4.2.12. Silver staining and distaining of SDS-PAGE 
SDS-PAGEs with the samples after PI3Kg immunoprecipitation were silver-stained 
according to Schevchenko et al. (1996). Briefly, the proteins were fixed in the gel with 50% 
methanol and 5% acetic acid for 20 minutes, then in 50% methanol for 10 minutes, followed 
by 10 minutes washing in the water. Sensitisation was made with 0,02% of Sodium-
thiosulphate for 1 minute, followed by two 1 min washing steps with water. The staining was 
performed with 0,1% of silver-nitrate for 20 minutes at the 40C in the dark, followed by two 1 
min washing steps with the water. The staining was developed with 0,04% formaldehyde and 
2% Sodium-carbonate. The developing was terminated with 5% acetic acid. The gels were 
stored in 1% acetic acid at 40C until further procedure. 
Distaining of the protein samples excised from the gel was performed according to the 
Gharahdaghi et al. (1999) in order to improve in-gel digestion and enhance the sensitivity of 
mass spectrometry identification. Briefly, distaining solution was made by mixing equal 
volumes of 30 mM potassium hexacyanoferrate (III) and 100 mM sodium-thiosulphate. The 
peaces of the polyacrylamide gel containing the protein samples were incubated in 1,5 ml 
micro test tubes with 200 µl of distaining solution for 8 minutes in Thermomixer (Eppendorf) 
at the room temperature, 1000 rpm. The samples were washed four times with the water, one 
minute each time with vortexing.  
 
4.2.13. In-gel tripsin digestion of proteins 
The peaces of the PAA gel after the distaining procedure were digested in-gel 
according to Mortz et al. (1994) with small modifications. The samples were soaked in the 
mixture of acetonitrile/water (2:3) and incubated for 20 minutes in Thermomixer (Eppendorf), 
1000 rpm, at room temperature. The liquid was removed and the peaces of gel were dried in 
the vacuum centrifuge for 20 minutes. The samples were rehydrated/alkalized with 50 µl of 
50 mM ammonium-hydrogencarbonate for 15 minute also in Thermomixer, 1000 rpm at room 
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temperature. Acetonitril/drying/rehydrating steps were repeated three times in total, except 
that the very last rehydrating step was replaced with the following one: 50 µl of the tripsin 
solution, concentration 60 µg/ml (sequencing grade methylated trypsin), was added to the 
each sample and incubated on ice for 20-30 minutes. The residue of the tripsin solution was 
removed and the peaces of the gel were soaked in 50 mM ammonium-hydrogencarbonate. 
The tripsin digestion was performed at 300C for 15 min followed by 370C incubation over 
night. Afterwards, the incubation solution was removed and stored in the separate tubes, while 
new 100 µl of the acetonitrile/water (3:2) solution was added to the samples and incubated on 
the Thermomixer for another 3 hours, 1000 rpm at room temperature. The removed 
incubation solution and the very last extraction solution were combined and the samples were 
lyophilised. The samples were stored at -800C until the further analysis. 
 
4.2.14. Mass spectrometry of peptides 
Mass spectrometry of peptides was done in the collaboration with Institute for General 
Botany and Plant Physiology, FSU-Jena, Germany. Lyophilised samples were resuspended in 
5 µl of water/acetonitrile/formic acid (95:5:0,1) prior to LC-MS analysis. Peptide analyses, 
analyte sampling, chromatography and acquisition of data were performed on a LC (Famous-
Ultimate; LC-Packings, Amsterdam, Netherlands) coupled with an LCQ Deca XP ITMS 
(Thermoelektron, San Jose, CA) according to the manufacturer’s instructions. The measured 
MS-MS spectra were matched with the amino acid sequences of tryptic peptides from the 
H.sapiens database in FASTA format. Raw MS-MS data were analysed by the Finnigan 
Sequest/Turbo Sequest software (revision 3.0; ThermoQuest, San Jose, CA). To identify 
corresponding loci, identified protein sequences were subjected to search with IPI data base 
(EMBL-EBI; http://srs.ebi.ac.uk). 
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4.2.15. RNA extraction  
RNeasy mini kit (Qiagen) was used for the extraction of total RNA from the Jurkat 
cells according to the manufacturer’s protocol. Briefly, 2x106 Jurkat cells per sample were 
collected 24 h after the activation along with corresponding control samples. The cells were 
lysed with 350 µl of RTL buffer per sample, and the lysate was homogenised with a 
QIAshredder spin column. Equal volume of 70% ethanol was added to the homogenised 
lysate and the samples were applied on the RNeasy spin columns. The columns were 
centrifuged for 15 second at 13 000 rpm. On-column DNase digestion was performed and the 
columns were first washed with RW1 buffer followed with two washing with RPE buffer. 
Finally, RNA was eluted from each column with 30 µl of RNase-free water and stored at       
–200C. 
 
4.2.16. Semi-quantitative RT-PCR  
Reverse transcription was performed using AMV Reverse Transcriptase (Promega). 10 
mg of total RNA was mixed with 100 pmol (dT)18 and 100 pmol random hexamer primer and 
heated at 700C for 5 min. Master mix, containing 5 µl AMV RT 5x buffer, 2.5 µl 10 mM 
dNTP’s and 2.5 µl AMV Reverse Transcriptase (300 u/ml), was added, volume was adjusted 
with RNAse free water to 25 µl and probes were incubated at 420C for 1.5 h. Semi-
quantitative RT-PCR protocol was performed as described by Halford et al. (1999) and 
Spadoni et al. (2003). Briefly, 5-fold or 10-fold serial dilutions of cDNA, prepared from total 
RNA, were used as RT-PCR templates. One twentieth volume of the resulting dilutions was 
subjected to PCR amplification using polymerase buffer (Qiagen) at 1x concentration 
containing 1.5 mM magnesium chloride, supplemented with 0.2 mM dNTP’s, 50 pmol PCR 
of each primer and 2.5 units Tag polymerase (Qiagen) in total volume of 50 µl. The PCR 
cycling was performed using an Eppendorf Mastercycler. The cDNA mixture was denatured 
at 950C for 2 min, followed by 30 (b-actin) or 40 cycles (IL-2) of 30 sec. denaturation at 
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950C, 30 sec. annealing at the temperature specific for each primer set (610C for b-actin, 570C 
for IL-2), and 60 s extension at 720C. PCR products were separated by electrophoresis in 
1,5% agarose gels containing EtBr (0.5 mg/ml) and visualised by UV transillumination. As an 
internal control of cDNA, PCR was performed on the same cDNA using primers for b-actin. 
The quantification of the signals’ intensity was made with AIDA Image Analizer Software 
version 3.22 (Raytest, Germany). 
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6. Abbreviations 
 
AP-1 - activating protein-1 
ATP - Adenosine 5'-Triphosphate 
BAD – BCL2 antagonist of cell death 
BCR - B cell receptor 
BTK - Bruton tyrosin kinase 
cAMP – cyclic adenosine monophosphate 
Con A - Concavalin A 
cpm- counts per minute 
DAG – diacylglycero 
DN - double negative thymocytes (CD4-/CD8-) 
DP - double positive thymocytes (CD4+/CD8+) 
EGF - epidermal growth factor 
ELISA - Enzyme Linked Immunoabsorbent Assay 
eNOS - endothelial nitric oxide synthetase 
ERK - Extracellular Signal-Regulated Kinase 
EtBr – ethidium bromide 
FACS - Fluorescent Activated Cell Sorter 
FDA - fluorescein diacetate 
fMLP - N-formil-Met-Leu-Phe 
FOXO - forkhead transcription factors 
FYVE domain - highly conserved zinc-binding domain named after four proteins first 
identified to contain it: Fab1p, YOTB, Vac1p, and EEA1 
GAPs - GTP-ase-activating proteins 
GEFs - TP/GDP exchange factors 
GLB – gel loading buffer 
GPCR – G-protein coupled receptor 
GTP - Guanosine 5'-Triphosphate 
IL-2 – interleukin 2 
IL-2R – interleukin 2 receptor 
INF-g - interferon-g 
Ins(1,4,5)P3 - inositol(1,4,5)triphosphate 
IONO – Ionomycin 
ITAM - immunoreceptor tyrosine-based activation motifs 
  6. Abbreviations 
 96
Itk - inducible T cell kinase 
IkBK - IkB kinase 
KI – knock-in 
KO – knock-out 
LAT - linker of activated T cells 
Lck- lymphocyte-specific protein-tyrosin kinase 
LPA - L-a-lysophospatidic acid 
LPS – lipopolysaccharides 
MAPK - mitogen activated protein kinase 
MCP-1 - monocyte chemoattractant protein 1 
MDC - macrophage derived chemokine 
MHC - major histocompatibility complex 
MIP-5 - macrophage inflammatory protein-5 
MS - mass-spectrometry 
NFAT - nuclear factor of activated T cells 
NFkB - nuclear factor kappa B 
NK cells – natural killer cells 
p38 – MAPK protein of 38 KDa 
PBS – Phosphate Buffer Saline 
PCR – polymerase chain reaction 
PDE3B - phosphodiesterase 3B 
PDGF - platelet-derived growth factor 
PDK1 – phosphoinosytide-dependent protein kinase 1 
PH domain – plekstrin homology domain 
PHA – phytohemagglutinin 
PI - propidium-iodide 
PI3K - phosphatidilinositide 3-kinase 
PIK domain - phosphatidilinositide kinase domain 
PKA - protein kinase A 
PKB/Akt - protein kinase B, also known as Akt 
PKC - protein kinase C 
PKD - protein kinase D 
PLCg1 - Phospholipase C gamma 1 
PtdIns – phosphatidylinositol 
PtdIns(1,4,5)P3 - phosphatidilinositol(1,4,5)triphosphate 
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PtdIns(3,4,5)P3 - phosphatidilinositol(3,4,5)triphosphate 
PtdIns(4,5)P2 - phosphatidilinositol(4,5)biphosphate 
PtdIns3P - phosphatidilinositol(3)phosphate 
PTEN - phosphatase and tensin homologue 
PTK - protein tyrosin kinase 
PVDF - polyvinylidene difluoride 
PX domain - pox homology domain 
RANTES - Regulated on Activation, Normal T cell Expressed and Secreted 
Ras-BD - Ras-binding domain 
Rlk – resting lymphocyte kinase 
SAPK/ JNK - Stress-Activated Protein Kinase/Jun N-terminal Kinase 
SDF1 - stromal-cell-derived factor 1 
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SGK - serum- and glucokorticoid-iduced protein kinase 
SH2 - Src-homology domain 2 
SHIP - SH2 domain-containing 5 inositol phosphatase 
SLE - systemic lupus erythematosus 
SLP-76 - Src homology 2-domain-containing leukocyte protein of 76 kDa 
TCR - T cell receptor 
TPA or PMA - phorbol 12-myristate 13-acetate 
VEGF - vascular endothelial growth factor 
Vps34p – vacuolar protein sorting protein of 34 KDa 
WT – wild-type 
ZAP-70 - z-chain associated protein kinase of 70 kDa 
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